Kinetic and docking studies of inhibitors targeting the catalytic zinc in MA clan enzymes by Sjøli, Stian
 
 
FACULTY OF HEALTH SCIENCE 
DEPARTMENT OF MEDICAL BIOLOGY  
TUMOUR BIOLOGY RESEARCH GROUP 
Kinetic and docking studies of inhibitors 





A dissertation for the degree of 
Philosophiae Doctor 
October 2011  
 
 
Table of Contents  
Acknowledgements…………………………………………………… i 
List of manuscripts………………………………………………….... iv 
List of abbreviations………………………………………………….. v 
Preface………………………………………………………………… vi 
Aim of Study………………………………………………………….. 1 
Introduction …………………………………………………………... 2 
1. Enzymes…………………………………………………………... 2 
1.1. Kinetics of Catalysis ………………………………………… 3 
1.2. Thermodynamics of catalysis ……………………………….. 6 
1.3. Breaking peptide bonds with water………………………….. 9 
1.4. Binding substrates……………………………………………. 11 
1.5. Substrate specificity………………………………………….. 11 
1.5.1. Catalytic chamber…………………………………….. 14 
1.5.2. Triple helical hydrolysis………………………………. 15 
1.6. Families of Metalloprotease………………………………….. 16 
1.6.1. Activation mechanism ……………………………….. 17 
1.6.2. M4 the Thermolysin family…………………………... 20 
Thermolysin………………………………………………. 20 
Pseudolysin……………………………………………….. 21 
1.6.3. M10A the MMP-1 family…………………………….. 22 




1.6.4. M13 the Neprilysin family……………………………. 25 
2. Pathological roles for MePs………………………………………. 26 
2.1. Tumor metastasis…………………………………………….. 26 
2.2. Bacterial invasion and sepsis………………………………… 28 
2.3. Extracellular matrix degradation…………………………….. 29 
2.4. Blood vessel regulation ……………………………………… 30 
3. Drug-aided treatment……………………………………………... 31 
 
3.1. M4……………………………………………………………. 32 
3.2. M10A………………………………………………………… 33 
3.3. M13…………………………………………………………... 33 
4. Inhibition …………………………………………………………. 34 
4.1. Activity towards isolated enzymes…………………………... 35 
4.2. Inhibition types ……………………………………………… 36 
4.3. Interpretation of Inhibition …………………………………. 38 
4.4. Exploring binding surfaces ………………………………….. 39 
4.4.1. Phosphoramidon……………………………………… 40 
4.4.2. TIMPs………………………………………………… 40 
4.4.3. α-macroglobulin………………………………………. 41 
4.5. Small-molecular ligands ……………………………………. 41 
4.5.1. The active site………………………………………… 42 
4.5.2. Hydroxamates………………………………………… 42 
4.5.3. Non-Hydroxamates…………………………………… 43 
4.5.4. Mechanism-based inhibitors …………………………. 44 
4.5.5. Exosites ………………………………………………. 45 
5. Free energy calculations…………………………………………... 46 
5.1. Modelling the system………………………………………… 47 
5.1.1. Protein structures……………………………………... 47 
5.1.2. Force fields…………………………………………… 48 
5.1.3. Energy minimisation………………………………….. 50 
5.1.4. Ion charges……………………………………………. 51 
5.1.5. Water problems……………………………………….. 51 
5.2. Docking ……………………………………………………… 52 
5.2.1. Docking with Glide…………………………………… 53 
5.3. Free energy perturbation……………………………………... 55 
5.4. Linear interaction energy…………………………………….. 55 
Summary of manuscript 1 ……………………………………………. 57 
Summary of manuscript 2 ……………………………………………. 58 
Summary of manuscript 3 ……………………………………………. 59 
Discussion ……………………………………………………………. 60 
6. Scavenging inhibitors …………………………………………….. 60 
7. Isolated enzymes …………………………………………………. 61 
8. Quenching………………………………………………………… 62 
9. Inhibition: Data collection ……………………………………….. 63 
10. Parameter assumption in assay design……………………………. 64 
11. Kinetic interpretations …………………………………………… 66 
12. Casuality …………………………………………………………. 68 
Future Perspectives…………………………………………………… 71 
References…………………………………………………………..... 72-99 
Attachments   
Manuscript 1…………………………………………………………..  1-29 
Manuscript 2………………………………………………………….. 1-25 























List of Manuscripts  
 
I. Stian Sjøli, Øyvind Wilhelm Akselsen, Yang Jiang, Eli Berg, Trond Vidar Hansen, 
Ingebrigt Sylte and Jan-Olof Winberg1 PAC-1 and Isatin 1,2,3 triazoles act as 
inhibitors in μM range of enclosed M10A, M13 and M4 enzymes. Manuscript 1.   
II.  Stian Sjøli, Elisa Nuti, Francesca Casalini, Irina Bilto, Armando Rosello, 
Jan-Olof Winberg, Ingebrigt Sylte and Olayiwola A. Adekoya. Synthesis, 
experimental evaluation and molecular modelling of a series of hydroxamate 
derivatives as pseudolysin and thermolysin inhibitors. Manuscript 2.  
III. Olayiwola A. Adekoya *, Stian Sjøli * , Irina Bilto, Sérgio M. Marques, M. 
Amélia Santos, Elisa Nuti, Giovanni Cercignani, Armando Rosello, Jan-Olof 
Winberg and Ingebrigt Sylte. The inhibition of pseudolysin and thermolysin by 









List of Abbreviations 
ECE: Endothelin converting enzyme 
ECM; Extracellular Matrix 
IC50; is the half maximal inhibitory concentration of a process. 
k: rate constant  
Km or Michaelis-Menten constant; the equilibrium dissociation constant for an 
enzyme and substrate 
Ki; the equilibrium dissociation constant for an enzyme and an Inhibitor 
LIE: Linear interaction energy  
MA(E): MA clan sub-group of families with a glutamic acid (E) as one of the zinc-
tethering residues together with two histidines 
MA(M): MA clan sub-group of families with three histidines as zinc-tethering 
residue. The MA (M) designation is based on a conserved methionine downstream of 
the catalytic triad that is incorporated in a structural fold - the «met-turn».  
MePs; Metalloendopeptidase 
MM: Michaelis-Menten 
MM/QM: Molecular modelling/Quantum mechanical modelling  
MMP; Matrix Metalloproteinases 
MMPI; Inhibitor of a MMP 
MT-MMP; Membrane tethered MMP 
PDB: Protein database 
proMMP; Inactive precursor of MMP  
TIMP; Tissue inhibitor of MMPs 
TLN; Thermolysin 
ECM; Extracellular Matrix 
Vmax; Highest (initial) velocity, or turnover rate, of an enzyme, and is the enzyme 
saturation point. 
















The subjects presented in the following could be combined in many ways depending 
on the reader’s preferences and pre-existing knowledge. The chosen outline is a circle 
starting with description of the smallest unit – the enzyme, the enzymes form families 
or clans of families, then certain pathological environments that they are known to act 
in is presented. This creates a step-wise biological complexity, which somewhat 
decreases afterwards from drug-treatment in the body to inhibitor design and to 
theoretical modelling of individual enzymes. Theoretical modelling of the enzyme-
inhibitor complex calculates approximations of free energy, which then builds on 
from the enzyme-section in the start. Catalysis (“Breaking peptide-bonds with water”) 
and substrate binding (“binding substrates”) might come prematurely for those that 
are not familiar with metalloproteases, and these readers might benefit from reading 







Aim of Study 
The aim of this thesis was to characterise inhibitors anticipated to target the catalytic 
zinc-ion found among other in enzymes from the M4, M10A and M13 families. This 
aim would be supported by the following smaller aims; 
 
I. Establish suitable FRET-assays and parameters for analysis of enzyme activity 
and inhibition   
II. Acquire numerical values of inhibition, IC50  and KI,  
III. Find and incorporate relevant enzyme-structures deposited in the Protein 
Database (PDB)  
IV. Dock the inhibitors in the different enzymes  
V. Correlate the numerical values of inhibition with the dockings, and 





















Enzymes are predominantly proteins catalysing chemical reactions in living 
organisms, and have occupied the minds of 17th century researchers as well as present 
day scientists [1-5]. These biocatalysts are life essential, and were initially seen as 
vital forces contained within, as well as in need of, the cellular environment. Before 
the eighteenth century, the process of digestion was believed to be solely a mechanical 
process, similar to a meat grinder. The digestion of meat by stomach secretions and 
the conversion of starch to sugars by plant extracts were explored. In 1750 Rene-
Antoine Reaumur fed his pet falcon pieces of meat enclosed in a metal tube with holes 
in it. He wanted to protect the meat from the mechanical effects of the bird's stomach 
friction [6]. When he removed the tube a few hours later, the meat had been digested, 
but the tube was still intact. It was evident that the digestion had resulted from 
chemical, not mechanical, action. Louis Pasteur coined the term «ferments» as the life 
force enabling yeast cells to ferment sugar to alcohol, and saw it as an act related with 
the life and organization of the yeast cell [7], while Wilhelm Kuhne first used the term 
«enzymes». This term was later used to refer to catalysis in non-living substances, 
while ferment was used to refer to catalysis by a living organism. Eduard Buchner 
described cell-free fermentation, which he attributed to enzyme «zymase» [8, 9]. 
Enzymes are, following his example, usually given the suffix -ase added to the name 
of the substrate they catalyse or the type of reaction when naming them. Enzymes can 
be crystallised, which allow structures to be solved by x-ray crystallography, and the 
structure of lysosyme was published in 1965 [10]. The biochemical studies on single 
enzymes began in the 19th century, but novel enzymes are still found and characterised 
on a daily basis today. Enzyme studies often investigate kinetic or thermodynamic 
properties of the reactions that the enzyme catalyses. Thermodynamical predictions do 
not require knowledge of the pathway between reactants and products, and give 
information on current properties. Thus, thermodynamics would focus on the initial 
state and final state, and potentially transition states that are long-living and stable 
enough to be identified (figure 1). Kinetics properties are dependent on the pathways 
from reactants to product. Kinetic properties can also reveal state-values as will be 




Figure 1:  Diagram of a reaction, showing the energy niveau with reaction coordinates. The 
reactants R are transformed into product P. This is nomenclature for chemical reactions, and 
in the next figures reactants will be named substrates. The areas of thermodynamics, marked 
in red, are internal properties of the stable states such as initial state (R) and final state (P) and 
potentially long-lived transition states (T). Kinetics, marked in blue, is dependent on the 
reaction pathway between R and P.     
 
1.1 Kinetics of Catalysis 
Enzyme kinetics is the study of the chemical reactions that are catalysed by enzymes 
[1]. A catalyst increases the speed to achieve equilibrium of a reaction. Rate laws 
studies the net turnover rate of a given reaction, and thereby connects the reaction 
equation to a time factor [11]. The turnover rate must be determined experimentally, 
and normally either the reduction of substrate or generation of product is followed 











1. r = k[A]x • [B]y 
2. k = A • e (E / (RT)) 
 
Equation 1,2: The rate. The equation consists of the rate (r), a rate constant (k), the 
concentration of two generic chemical species A and B (as an example), while x and y are 
coeffiecients that needs to be determined experimentally. In equation 2, A is the pre-
exponential factor, E is the activation energy, and R is the gas constant, T is the temperatur 
in kelvin.   
 
The enzyme catalyses both directions, meaning that it is reversible (figure 2), but one wants to 
treat it as composed of two irreversible reactions [1]. This can for instance be done by starting 
far from equilibrium in the early phase with only substrate, and remove the reverse reaction 
catalysis.  
 
Figure 2: Illustration shows the two steps in an enzyme-catalysed reaction. Enzyme (E) binds 
to substrate (S) and form a complex (ES). The ES dissociates into E + S or E + P or associates 
from them. Total association is governed by k1 +  k-2 and total dissociation by k-1 + k2.   
 
The assumption of quasi-steady state, in which substrate-bound enzyme ([ES]) 
changes much more slowly than substrate ([S]) and product ([P]), allows the amount 
of formed complex to be regarded as fixed. The total amount of enzyme, [E]tot, is 
always the sum of free, [E]free and bound forms, [ES] and [EP] when the dissociation 
of product is a slow step [12]. The enzyme has one or sets of active sites where the 
catalysis occurs, and can not work faster when all of these active sites are occupied by 
substrate. The enzyme therefore achieves its highest initial velocity, designated Vmax, 




3. Etot = Efree + ES 
4. V0 = Vmax · [S] / Km + [S]  
when [S] > Km then [E]tot ≈ [ES]  and Vo = Vmax = k2 · [ES]    
when [S] = Km then [E]tot = ½ [ES] + ½ [E]free  and Vo = ½ (k2 · [ES])       
when [S] < Km then [E]tot ≈ [E]free and Vo = (k2/Km) · [E]· [S]      
 
Equation 3, 4: Relationship between enzyme-forms (1) and initial velocity equation (2). Etot 
is total enzyme amount, Efree is unbound (free) enzyme and ES is enzyme-substrate complex. 
V0 is the initial velocity, Vmax is the maximal velocity denominator, [S] is substrate 
concentration, Km is the Michaelis-Menten equilibrium constant.  
 
The Michaelis - Menten constant, Km, is the substrate concentration for which the 
reaction achieves half of the Vmax [13]. According to the following equation, this 
entity will be low in cases where the enzyme has a high affinity for the substrate or 
stated differently; ES formation (k1) is higher than the rate of ES dissociation (k -1 + 
k2). This constant is independent of enzyme amount since it is usually in shortage 
compared to the substrate. The reaction might have several intermediate steps, govern 
by thermodynamics, but ultimately the rate limiting step will be the slowest reaction 
step. The Kcat relates the Vmax to [E]tot . The specificity constant is a ratio between 
substrate binding (Km) and subsequent turnover to product (Kcat). The specificity 
constant describes the full reaction scheme, incorporating the rate constants for all the 
steps in the forward reaction. It can be seen as a measure of how efficiently an 
enzyme traverses a given substrate along the reaction pathway. This constant relates 
only to one substrate. Because the constants reflect both affinity (Km) and catalytic 
ability (Kcat), it is useful for comparing different enzymes against each other, or a 
comparable measure of the adaptation of different substrates to the same enzyme. 
 
5. Km = (k -1 + k2) / k1 
6. Kcat = Vmax /[E]tot 
7.  Ksp = Kcat / Km 
 
Equation 5, 6, 7: Equilibrium constants describing enzyme properties. Km is the Michaelis-
Menten constant, Kcat is the equilibrium constant for the catalytic step and Ksp is a fraction 
with numerator Kcat and denominator Km.   
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This constant relates only to one substrate. Because the constants reflect both affinity 
(Km) and catalytic ability (Kcat), it is useful for comparing different enzymes against 
each other, or serve as measure of the adaptation of different substrates to the same 
enzyme. The reaction rates, which are kinetic properties, can be used to find 
equilibrium constants of a given reaction, as for instance seen with equation 5, which 
subsequently enables us to calculate approximate values on thermodynamic 
quantities, such as Gibbs free energy (see equation 10).   
 
1.2 Thermodymics of Catalysis 
All reactions are systems that imposes work on the surroundings [14]. Molecules 
destined to react with each other move around at different speeds dependent on their 
energy, and they collide with each other and the container. For a reaction to progress 
favourably collisions between reactants are necessary, and the collision angle, the 
relative translational energy, the internal (particularly vibration) energy will all 
determine the chance that the collision will produce a product molecule. Reactions 
have (a) short-lived intermediate(s) with a higher energy than the reactants creating an 
energy-barrier to cross. Molecules not able to achieve the activation energy will not 
traverse the energy-barrier and will not progress to product. Thus, a spontaneous 
reaction, meaning that it releases energy during progression, might still be stagnant or 
have a long reaction time if it is unable to cross this barrier. Catalysts, such as 
enzymes, lower this transition state energy barrier (see figure 3). The enzyme might 
do this by for instance offer proximity and aid orientation between two reacting 
molecules, donate a surface of electrostatic charges or a stabilising hydrophobic 
environment, form covalent intermediates with the substrate or even quantum 
tunnelling. The catalyst will return back to its initial state after catalysis. Reducing the 
activation energy leads to more product since more reactant molecules have enough 
energy to traverse the new energy barrier (figure 3 top). The enzyme thereby 
accelerates the time it takes to reach equilibrium by stabilising this transition state. 
Gibbs (free) energies (ΔG) are state functions that express the spontaneity of a 
chemical process in terms of enthalpy and entropy changes under conditions of 
constant temperature and pressure and is convenient for evaluating among other in 




8. ∆G (p,T) = U + pV − T∆S 
9. ∆G(p,T) = ∆H − T∆S 
10. ∆G(p,T) = -RT • lnK 
 
Equation 8-10: Gibbs free energy ∆(G(p,T)) as a function where p is pressure, T is absolute 
temperature, U is the internal energy of the system, V is volume,  and S is entropy while H is 
the enthalpy of the system. R is the gas constant and K is the equilibrium constant.   
 
The enzyme-catalysed reaction has several energy barriers to cross; in binding the 
substrate among other because it costs energy to de-solvate the substrate in entering 
the enzyme cavity (figure 3 bottom, step 1), activating and reorienting the substrate 



























Figure 3:  Diagram of a reaction without or with enzyme, showing the energy niveau with 
reaction coordinates (top). The reactants S, substrate, is transformed into product (P), and 
their respective internal energies are the same despite the potential different reaction pathways 
(enzyme-catalysed versus un-catalysed). Diagram of a reaction with enzyme, showing the 
energy niveau with reaction coordinates (bottom). Here is shown a more detailed view of the 
energy-barriers for the different steps in an enzyme-catalysed reaction. Area of interest in 
kinetics, marked in blue, and is dependent on the reaction pathway between the different 








1.3 Breaking peptide bonds with water 
The peptide bond is metastable and will uncatalysed break apart in water [15]. 
However, this process is slow. Hydrolytic enzymes, such as metalloendopeptidases 
(MePs) are able to break such bonds in peptides or proteins [16]. Proteases can be 
endopeptidases, which means that they cleave internal peptide bonds in substrates, or 
exopeptidases, which cleave terminal peptide bonds [16]. Exopeptidases can be 
further subdivided into aminopeptidases and carboxypeptidases [16]. The MePs are 
endopeptidases that are active at neutral pH [17, 18], but some can also have other 
substrate-dependent preferred pH-ranges [17], have a broader pH-range of activity 
[19] or be active at a lower pH [20]. MePs distinguish themselves from other 
endopeptidases by their dependence on metal ions as cofactors. The fact that some 
catalytically important amino acids are conserved among these enzymes suggests the 
evolution of a shared catalytic mechanism. Discoveries on individual enzymes might 
be transferable to other enzymes, and for instance thermolysin has been a prototype 
enzyme for other MePs [21]. Despite a wealth of information, there is so far no 
consensus on catalytic mechanism, but several suggestions agree at some points while 
diverge at others. Recruitment and positioning of a varying number (1-3) of water 
molecules is vital [22, 23]. One of these water molecules interacts with the zinc-ion 
and forms hydrogen bonds with a glutamate residue adjacent to the first histidine in 
the zinc-binding motif (see figure 4). This has been supported by x-ray structures as 
well as inactive mutants of this glutamate [24]. Crabbe et al. found the same for three 
mutant forms of proMMP-2 [25]. The proposed reaction mechanism by Matthew et al. 
is shown in Figure 3 [26]. The zinc-ion is now pentacoordinated with three 
interactions tethering it to the enzyme. These three interactions are either all histidines 
for the metcinzins or two histidines and a glutamate for the gluzincins (see figure 6). 
In an intermediate, the glutamate has removed the hydrogen completely, and donated 
it to the amine-group. An oxygen atom of the carboxyl-group interacts with the 
donated hydrogen atom through hydrogen bonding. There are also hydrogen bond 
interactions formed between the substrate peptide and amino acids in the enzyme that 
acts to stable the transition form (aa1 and aa2). In the M4 family, aa1 is a tyrosine 
(Tyr157 in TLN) while aa2 is a histidine (His231 in TLN). The histidine is further 
stabilised by an aspartate (Asp226 in TLN). These amino acids have analogues in other 
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MePs, for instance Neprilysin [27-31]. The peptide bond is broken, resulting in the 
release of an amine and formation of an enzyme-carboxylate complex. The 




Figure 4: Proposed catalytic mechanism of peptide bond cleavage. The illustration shows the 
catalytic zinc-ion interacting both with a water molecule (that also interacts with a glutamate 
residue) and a peptide (bottom left), the water acts as a nucleophile and the peptide as 
electrophile (top) and the Enzyme-Carboxylate complex and amine product. The illustration is 
made with ChemBioDraw Ultra version 12, and is inspired by [26]. 
 
Enzymes can undergo conformational changes necessary for catalysis [32, 33]. There 
are some suggestions that TLN and related bacterial enzymes go through dynamic 
movements in the hinge-region that connects the C-terminal domain to the N-terminal 
domain [34]. These movements lead to a closer interaction of some of the amino acids 








1.4 Binding Substrates 
Enzymes initiate binding to their substrate before catalysis, and it was first believed 
that the active site was complimentary shaped to the substrate (lock and key model 
[35]). It was later suggested that a perfect complimentary fit would create a co-
stabilisation halting catalysis altogether, and a “induced fit”-model was suggested 
instead [36, 37]. Protein structure flexibility might also be used as an active means of 
gaining selectivity [37-40].  The binding energy needs to be strong enough to support 
a complex, but at the same time weak enough to catalyse the reaction and for the 
complex to dissociate [36]. This is supported by a balance between enthalphy- and 
entropy- terms. Enzymes themselves are stabilised by the effect of many (mostly 
weak) interactions between amino acids in the range of 30-65 KJ/mole, which is 
equivalent to only a few weak hydrogen bonds [41]. Thus, only a few intermolecular 
interactions between substrate and enzyme might have great impact on the stability of 
the complex. Hydrophobic and electrostatic interactions are inter-molecular non-
covalent forces in the interaction [42-44], but also covalent bonds between enzyme 
and substrate can be formed and broken during catalysis [5, 45]. Hydration of non- 
hydrophobic interactions and inter-peptide attractive effects (hydrogen bonding, salt 
bridges, and classical van der Waals 6-12 type interactions) are of general stabilising 
nature, whereas for instance desolvation of the substrate and enzyme binding sites are 
energy-costly and serve as barriers promoting the destabilisation of the complex. 
 
1.5 Substrate specificity 
An enzyme might act on a few [46] or several substrates [47], depending on how 
unique the substrate properties that is recognised by the enzyme are [48, 49]. The 
ability to select preferred substrates resides in specificity. One of the factors 
contributing to specificity is making favourable interactions between the enzyme 
binding pockets, and corresponding residues in the substrate [50]. A binding-pocket is 
usually a cavity on the enzyme that attracts a certain charge or hydrophobic nature on 
the substrate-residues to complement its own charges inside the pocket. The 
architecture of the pocket can combine a largely hydrophobic surface with a charged 
bottom. This helps to focus the charge or the pocket might have asymmetrical charge 
distributions throughout the surface.  The volume of the pocket is a result of the 
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structure, which is constantly vibrating and moving. Pockets are also often formed by 
flexible loop regions. Amino acid-residues lining the pocket may be directed inwards 




Figure 5: Substrate-binding pocket. The illustration shows an enzyme pocket (left) with one 
charge (red) and a substrate with the opposite charge (blue). The enzyme pocket (right) has a 
structure were the volume is dependent on the depth and width. An amino acid residue might 
be directed inwards so that the residue forms the bottom or might be directed outwards. The 
amino acid backbone will determine the bottom of the pocket if the residue is directed 
outwards creating a larger volume.      
 
There are usually several sub-pockets close to the catalytic triad [51], generally 
extending from S3 to S4` in MePs [52]. The three dimentional structure creates a fold 
so that pockets can be side-by-side on one side along an imaginary horizontal axis on 
the substrate or on opposite sides of this axis. Subsites are numbered S1–Sn upwards 
towards the N terminus of the substrate (non-primed sites), and S1′–Sn′ towards the C 
terminus (primed sites), beginning from the sites on each side of the scissile bond 
[53], and the substrate residues they accommodate are numbered P1–Pn, and P1′–Pn′, 






Figure 6: Substrate-binding pocket nomenclature. The illustration shows an enzyme active 
site with substrate. Subsites are numbered S1–S2 upwards towards the N terminus of 
the substrate (non-primed sites), and S1′–S2′ towards the C terminus of the substrate 
(primed sites). Primed or non-primed sites are on opposite ends of a vertical axis of 
the sciccil-bond. The arrow points to the sciccil bond.  
 
A substrate might interact perfectly with all sub-pockets creating a strong interaction, 
or marginally with several pockets still with enough additive strength for binding. A 
few (or one) sub-pocket(s) being dominant might also be a possibility. It is also 
possible that some pockets interact negatively with the substrate, and then the other 
sub-pockets might compensate for the negative interactions of this pocket (securing 
substrate binding) or they might not, in which case the putative substrate is not bound 
and not an substrate anymore. Uniting sub-pockets is thus a molecular mechanism that 
may create specificity in some cases, while promiscuicity in others. For instance, 
MMP-2 have been investigated with peptide libraries in order to map molecular 
recognition [54]. Small amino acids, such as alanine and glycine, were preferred in 
P1, but also asparagine and aspartate was accepted. Leucine in P1’ (46 %) forms the 
predominant molecular specificity of MMP-2 along with other large hydrophobic 
residues. In P2’, the MMP-2 preferences included basic amino acids, notably de-
methylated lysine formed during library preparation, and large hydrophobic residues. 
The P3’ preferences included the small amino acids alanine, glycine and serine. This 
shows adaptation in individual pockets. However, the amino acid composition of the 
substrates seldom (fewer than 5 %) had optimal residue-interactions at all sub-sites. A 
given substrate would thereby create a number of optimal fits together with non-
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optimal ones (neutral or potentially negative), which might help to explain the 
cleavage-site promiscuity of the enzyme – and inferred on the MMPs as a group. 
Substrate specificity is also regulated by overall structure of the active site, or even 
the global protein structure. MMPs and Thermolysin, have an exposed shallow active 
site cleft that enables them to catalyse break-down of both smaller and larger 
substrates [55]. In contrast, the neprilysin family are biased favouring smaller peptides 
instead of proteins [56]. An enzyme might also combine two catalytic processes in 
order to broaden substrate reportoar, such as the MMPs that have an additional triple 
helical activity that enables them to cleave bigger and more complex substrates [57].  
 
1.5.1 Catalytic chamber 
Neprilysin, NEP-like enzymes and Insulysin have a catalytic chamber that can 
encapsulate their substrate and for this reason they are referred to as cryptases [56]. 
The smaller entry port into the chamber contributes to substrate specificity by 
excluding larger proteins from gaining access to the active site (figure 7). The 
substrate selectivity is also determined by the size and charge distribution of the 
enzymes crypt as well as the conformational flexibility of substrates [56]. The NEP-
like enzymes cleave amyloid -β peptides of 36-43 amino acids that are known to 
aggregate and form abnormal deposits in the brain of Alzheimers patients [56, 58]. 
The protein fold adapted by these peptides in the deposits are shared by for instance 
prions, which are disease-associated misfolded proteins [59]. The aggregates also 
possess an internal motif of four amino acids, FAED, which is similar to the putative 
TGF-β active site, WSXD. This similarity might explain why TGF-β is a substrate for 
these enzymes. The motif might also transfer TGF-β activity onto the amyloid-β 
proteins [60]. This illustrates that size and sequence-recognition in the substrate is 








Figure 7: Illustration of restricted entry into the catalytic of NEP-1. The protein is coloured in 
gold and the zinc-ion is silver-coloured. A blue surface is generated that lines the borders of 
the entry into the active site (residues not specified). The illustration is made within Maestro 
(Schrödinger).  
 
1.5.2 Triple helical hydrolysis 
Some of the MePs are able to cleave substrates that are fibres [61-64]. Fibres consist 
of peptides or proteins, which have polymerised into longer chains of protein 
subunits. The collagen fibre consists of three α-chains of approximately 1000 residues 
with repeating Gly- X (often Pro)- Y (often HYP), which adopts a left-handed poly-
Pro II like helix [63-65]. Three of these α-chains intertwine to form a right-handed 
superhelix, and the structural complexity makes it resistant to proteolysis by most 
enzymes [63, 65-67]. Several MMPs have been shown to poses collagenolytic activity 
[68, 69]. The ability of each enzyme to efficiently hydrolyze the triple helix is 
varying, and the gelatinases are weaker collagenolytic enzymes than for instance 
MMP-1 [61]. Ability to cope with thermal substrate stability has been shown to be 
important for catalysis [69, 70], while also substrate residues might facilitate local 
unwinding [71]. Enzymes also need regions outside of the active site for their affinity 
towards high-molecular-weight substrates, which are sometimes referred to as 
exosites. The helix needs to be unwound, and work on a catalytically inactive MMP-1 
showed that the helicase activity was not depended on the catalytic glutamate [72]. 
The enzyme can also move on the larger substrate [73, 74]. MMP-2 and -9 apparently 
required their inserts of FnII-like modules to hydrolyze elastin [75], collagen [76-79], 
and THP mimics of collagens [80]. MMP-2 has a collagenase activity, and the 
catalytic and hemopexin domains were shown sufficient to cleave rat type I collagen 
[81]. A later study found that collagen cleavage was reduced without the fibronectin 
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repeats, and found indications that MMP-14 and MMP-2 bind collagen at a different 
site than MMP-11 and MMP-8 [79].  MMP-9 has also been found to cleave triple 
helical collagens [82]. The formation of fibers exemplifies that increased structure 
complexity of the substrate also can lead to substrate specifity.    
 
1.6 Families of Metalloproteases 
It is estimated that about 2 % of the human genome constitute proteases [83, 84]. 
These are broadly grouped in five main types depending on the amino acid residues 
important for catalysis [85]. The largest class recruit a metal-ion as a prosthetic group 
[85]. The metalloproteases are  among the most structurally and functionally diverse 
types of enzymes, but share a number of functional properties such as pH optimum 
near neutral, inhibition by chelating agents and resistance to inactivation by other 
reagents. 80 families are so far annotated in the MEROPS database [86, 87]. The 
largest category of the metalloproteases, and also metalloproteins in general, tether a 
catalytic zinc-ion to their active site. In general the zinc-binding is usually performed 
by three amino acid residues, these are either His, Glu, Asp or Lys residues as they are 
known metal-binding residues. The HEXXH motif is relatively common among all 
proteins, but is a shared and defining characteristic among the majority of zinc-
metalloproteases. This motif is often “abXHEbbHbc”, where “a” is most often a 
valine or threonine, “b” is an uncharged residue while “c” is a hydrophobic residue. 
The metalloenzymes with this motif belongs to the MA clan (MA). MA includes 
several enzyme families of pharmacological or biotechnological interest, which all 
require one catalytic metal ion that in most cases is zinc. Thereby, the clan (together 
with the ME clan) differs from other clans (MF, MG, MH, MN and MQ) that 
coordinate two metal ions acting in collaboration on the substrate in order to complete 
the catalytic process [88]. MA(M) and MA(E) are both in MA, and are commonly 









Figure 8: Illustration of the catalytic triad interaction with zinc-ion in MA (E) (left) and MA 
(M) (right). The illustration is made with ChemBioDraw Ultra version 12.  
 
The MA(E) enzymes all have a glutamic acid as one of the zinc-tethering residues 
together with two histidines, while the MA(M) has three histidines. The MA (M) 
designation is based on a conserved methionine downstream of the catalytic triad that 
is incorporated in a structural fold - the «met-turn» [89].  
 
1.6.1 Activation mechanism  
MePs are sometimes produced as inactive precursor enzymes [90, 91]. Activation of 
these precursors then becomes an important posttranslational regulation mechanism. 
MMPs exemplifies this, and it was early believed that the MMPs were kept inactive 
by inhibitors and that they were activated as a consequence of inhibitor-removal from 
the enzyme-inhibitor complex, either through proteolysis or dissociation of the 
inhibitor [92-94]. Studies on human fibroblast collagenase (HFC) found that all 
modes of activation tested lead to dissociation of the cysteine residue (Cys75) from the 
zinc atom with following exposure of the active site [93, 94]. It was then proposed 
that this residue in the propeptide domain was oriented towards the catalytic zinc-ion 
in the inactive enzyme, thereby blocking the access to the active site, and that upon 
activation this interaction was broken [93, 94]. The interaction can be broken by 
dislodging the N-terminus, where the cysteine is found, so that a water-molecule can 
enter and initiate autolysis or by enzyme-cleavage (figure 9) inside the bait region to 
expose the catalytic zinc-ion. The partially active enzyme can remove parts of its N-
terminus, where the cysteine residue is located, in an inter-autoactivation reaction thus 
acquiring full activity. This lead to the idea of a “cysteine switch” since the cysteine 
residue is “off” when the protein is active and “on” when the protein is in its inactive 
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form. Later studies found that this cysteine residue is conserved in most known 
MMPs, and these are probably all activated in this manner [94, 95]. The cysteine-
switch has for some enzymes not been sufficient for activation [96] and there are 
alternative pathways [97]. There are also novel MMPs discovered without the 
classical cysteine switch [98, 99]. In pseudolysin, the propeptide is cleaved in the 
periplasm but remains associated with the mature peptide and this non-covalent 
complex is inactive. It has recently been suggested that the propeptide contains a 
peptidase inhibitor domain known as 'pepSY' [100]. The N-terminal propeptides are 
autocatalytically removed, and it has been shown that this propeptide-part assist in 
folding of the protein [101]. Enzymes can be dependent on other factors, such as salt, 






























Figure 9: Activation of a precursor MMP. Aspects of the illustration such as cleavage and 
activation by another enzyme and/or auto-activation may apply to other MePs. The zinc-ion in 
the precursor enzyme is blocked from interacting with water by a peptide extension, allowing 
a cysteine-residue to replace the water molecule in interacting with the zinc-ion. After an 
enzyme cleaves in this region, the catalytic water molecule enters the active site and the 
precursor gains partial activity, even though the cysteine residue is still present, and can 
activate itself further. Now the cysteine-residue is removed and full activity is gained. An 
Enzyme might cleave in collaboration with a second enzyme (enzyme 2) or enzyme 2 might 











1.6.2 M4 the Thermolysin family 
Eubacterial endopeptidases that are secreted by both gram-positive and gram-negative 
bacteria with similarity to thermolysin are found in the M4 family [106]. Most 
members of the family degrade extracellular proteins and peptides for bacterial 
nutrition, especially prior to sporulation, but they can also be used as virulence factors 
[21]. A small subset of amino acids dictates substrate specificity among M4-proteins 
[107]. Most members of this family have a preference for cleavage of Xaa+Yaa, in 
which Xaa hydrophobic residue and Yaa is Leu, Phe, Ile, or Val and  primary for an 
aromatic residue in P1’ [108, 109]. There are so far 24 family members, with at least 
an experimentally determined structure for five according to the MEROPS database . 
There are 125 hits in the PDB-database for thermolysin alone, but individual hits 
should be carefully reviewed to make sure that all are thermolysin structures. The 
enzymes have a two-domain structure with the active site between the domains [110]. 
The N-terminal domain includes a distinctive six-strand beta sheet with two helices, 
one of which carries the zinc-tethering catalytic triad.  This N-terminal domain is 
similar in other families (for instance M10) while the C-terminal domain is unique for 
the family, is predominantly helical and carries the third zinc ligand involved in 
stability. Some of the thermolysin structures are co-crystals with inhibitors, address 
structural changes in solvent or radiation-response or represent the enzyme alone. 
Msp protease from Legionella may have a role in the virulence of Legionaire’s disease 
[111]. Vibriolysin from Vibrio cholerae is a haemagglutinin that has been shown to 
affect intracellular tight junctions by degrading occludin [112].  
 
Thermolysin 
Thermolysin (TLN) is a neutral metalloproteinase enzyme with a molecular weight of 
34.6 KDa initially discovered to be secreted by Bacillus thermolyticus Rokko in 1962 
[21]. TLN degrades extracellular proteins and peptides that are subsequently taken up 
by the bacteria as nutrition. The bacteria are an extremophile, meaning that it thrives 
in high temperature environments, necessitating temperature-stable enzymes [21]. 
TLN exemplify this by retaining half of its activity following incubation at 86.9 
degrees for 30 minutes [113, 114], and shows no signs of any major conformational 
changes associated with denaturising until at least 70 degrees. In 1972, thermolysin 
became the first metalloprotease for which a structure could be determined by 
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experimental methods [110]. The enzyme was found to consist of two roughly 
spherical domains separated by a deep cleft. The N-terminal domain consists mostly 
of beta-sheets, while the C-terminal domain is dominated by alpha helixes. The 
authors had to re-examine the electron density maps on the original thermolysin 
structure, assumed to represent free enzyme, and found that it probably contain a 
dipeptide in the active site and instead correspond to an enzyme-inhibitor or enzyme – 
substrate complex [34]. Thermolysin hydrolyses specifically peptide bonds on the 
amino side of large hydrophobic residues [26, 115, 116], and may therefore also used 
in partial fragmentation of proteins prior to Mass spectrometric analysis [117]. The 
enzyme has been used in the location of disulfide bridges in molecules resistant to 
other proteases [118]. Thermolysin is also used to catalyse the formation of precursor 
molecules of aspartame [119], which is an artificial sweetener, and is included in 
washing liquids for degrading protein stains on clothes. Less of the bitter-tasting by-
products are formed during aspartame-synthesis catalyzed by thermolysin. 
Thermolysin is also widely used in reverse hydrolysis reaction forming peptide bonds 
between supplied precursor molecules, has uses in prion disease diagnosis [120] and 
has also aided discovery of putative inhibitors towards other enzymes for which it 
shares some active site features, for instance Neprilysin and MMPs [121].  
 
Pseudolysin 
Pseudolysin is 33 KDa large enzyme with an isoelectric point of 5.5 [122, 123] with 
the first structures resolved by x-ray in 1991 [124, 125]. There are currently three 
structures deposited in the PBD-database (accession numbers: 3DBK, 1U4G, 1EZM), 
and the enzyme is similar to thermolysin both by sequence, structure and partially in 
substrate preferences. Pseudolysin has a more open substrate-binding cleft compared 
to thermolysin and contains four cysteine residues, which form disulfide bonds with 
their nearest nabours and has one calcium ion-binding site, while thermolysin bind 
four calcium ions and has no cysteine residues [21]. Pseudolysin seems to first have 
been cloned and expressed in 1987 [126], but the elastase cleaving properties of 
Pseudomonas aeruginosa isolates had already been known for more than 20 years 
before this time [127]. Studies included works on the strain isolates themselves [128] 
as well as investigations with partially purified protein extracts [129]. There are 
several site-directed mutant produced that verify residues involved in either catalysis 
[130-134] and/or substrate-binding. There are several substrates found for this enzyme 
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[135]. Pseudolysin is the major virulence factor of Pseudomonas aeruginosa 
septicaemia, causing tissue damage (especially in the lung where elastin is degraded) 
and may compromise the immune system by degradation of immunoglobulins, 
complement components and serpins. 
 
1.6.3 M10A the MMP-1 family 
The matrix metalloproteinases constitute the M10A family according to the MEROPS 
database [136]. The founder enzyme is MMP-1, or trivial name interstitial 
collagenase-1, that was first found present and active in tadpoles undergoing 
metamorphosis [137, 138]. The enzyme was found involved in collagen metabolism, 
and a human ortologue enzyme was first identified in rheumatoid synovium. There are 
at present 24 counted family members, who includes two connected identical genes of 
MMP-23, or 23 non-redundant members [139]. The zinc-binding motif in this family 
consists of the consensus sequence HEXGHXXH and a conserved methionine eight 
residues downstream this sequence that forms a «Met-turn» [140]. MMP-1 can be 
dissected into a signal peptide region, a prodomain, a catalytic domain, a linker 
sequence followed by a C-terminal domain homologues to hemopexin and vitronectin 
(hemopexin domain) [141, 142]. These features are all found in individual family 
members, except that MMP-7 and MMP-26 are truncated without the hemopexin 
domain and others may have additional domains. These additional domains are for 
instance three fibronectin type II domains found in the active site of MMP-2 and 
MMP-9, or stalk regions and transmembrane domain seen in MT1-MMP [142, 143]. 
Combined the family members can cleave several static extracellular components 
such as collagen that normally are very resistant to turnover [144, 145], and they have 
recently been found to have broader activities acting on for instance cytokines and 
participate in regulating other signalling molecules [146-167]. There are also 
suggested intracellular locations and substrates for some of the MMPs [168]. The 
individual family members can be regulated on a transcriptional level, by 
compartmentalisation, regulation of access to their substrate and by native inhibitors. 
The TIMPs, tissue inhibitors of MMPs, are one example of native inhibitors of these 
enzymes. MMPs seem to touch almost every aspect of mammalian biology, and there 







Two M10A family members have been found active towards denatured collagens, and 
these are MMP-2 (also known as gelatinase A) and MMP-9 (also known as gelatinase 
B) [61, 143]. Three fibronectin repeats inserted in the active site separates these 
enzymes from other MMPs [77, 78, 169, 170]. Variations in the substrate specificity 
of the gelatinases suggest that they have different sub-site preferences [171]. MMP-2 
remains the most widely expressed MMP, and is produced constitutively by cells in 
culture as well as in tissue environments, while MMP-9 has an induced expression 
pattern in fewer cell types [172-175]. Both gelatinases are found in plasma, while 
MMP-9 also in the saliva. Human proMMP-9 is predicted to be slightly larger than 
proMMP-2 (~76 KDa versus 72 KDa), which in part is explained by a longer hinge-
region. SDS-PAGE indicates a size of 92 KDa for proMMP-9 (105 KDa in mouse), 
and the extra mass has been shown to be due to N- and O- linked glycosylation [175]. 
Both gelatinases are inhibited by zinc-chelators, among their unique features is the 
binding of their proforms to TIMP-1 (gelatinase B) and TIMP-2 (gelatinase A) [175, 
176]. They are differently regulated at the transcriptional and extracellular level, and 
may sometimes differently impact on the same disease [177]. 
 
MMP-2 
MMP-2 was the first of the M10A gelatinases to be discovered [178], and is 
constitutively expressed by many cell types [172]. MMPs are often inducible and 
tightly regulated on a transcriptional level, and the constitute expression has been 
linked to several differences (compared with other MMPs) in elements in the 
promoter-region [172]. The protein activity has been suggested to be regulated on a 
posttranslational level by; secreting, compartmentalisation, activation and inhibition 
[179, 180]. Because of the known involvement of MMP-2 in pathological disease 
[181], there have been several attempts to find good inhibitor drugs specifically 
inhibiting this protein (inhibitor-chapter in this thesis). The enzyme has been 
crystallised [95] . Unlike the collagenases (MMP1 and MMP8), which uses the 
hemopexin-like domain to bind and position substrate for cleavage at the active 
catalytic domain, MMP-2 uses the C-terminal domain to bind cell surface attachment 





MMP-9 is the second member of the matrix metalloproteinase family that is 
recognised to be a gelatinase, and was found in 1974 [182]. The number “9”-
designation was given after a MMP meeting in 1989 [143]. The proteolytic activity 
was investigated using different sources [183, 184], and it was found to migrate 
slower than MMP-2 in a gelatine zymography. The size was found to be ~90-110 
KDa. Human proMMP-9 is predicted to be slightly larger than proMMP-2 (~76 KDa 
versus 72 KDa), which in part is explained by a longer hinge-region, but extra mass 
has been shown to be due to N- and O- linked glycosylation [185-187]. Cancer-
associated glycoforms of the enzyme has been found [188] and also shown to 
influence on binding-strength to some substrates [189]. MMP-9 contains all the 
typical domain structures of the MMPs, but like MMP-2 has three fibronectin repeats 
in the active site. These repeats have sequence differences. The hinge-region is longer 
and more flexible in MMP-9 than MMP-2 because of a unique collagen V like domain 
found here. Gen expression is regulated so that the enzyme is normally expressed by 
trophoblasts, osteoclasts, neutrophiles and macrophages, but the expression is 
inducible [190, 191] and the enzyme has been found expressed in [192-195]- and 
contributing to- several pathologies [196-202]. There are several substrates, either 
cytokines or larger ECM components [203].  
MMP-14  
MMP-14 was the first membrane-tethered MMP to be discovered, and has since then 
received a lot of research attention [204]. The enzyme has also been found to act as an 
important in vivo - activator of other MMPs [204]. MT1-MMP is shown to form a 
ternary complex with TIMP-2 and proMMP-2, which can lead to activation of MMP-
2 [205]. It was first propoused that the complex creates an intermediate active MMP-
2, which gains partial activity and subsequently mature to the fully active form [205]. 
In a supplementary activation pathway, proposed by Lafleur et al., TIMP-2 aids in the 
maturation of the intermediate, but is not essential for the formation of the 
intermediate [206]. The discovery of the MMP-14 activation pathway paved the way 
for findings on other membrane tethered MMPs in the activation of proMMP-2 [207]. 
MMP-14, has shown to infer malignancy to non-tumorigenic as well as tumorigenic 
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cell lines, frequently expressed by many types of cancer cells [208], is the only MMP 
that in knock-out mice causes lethality and has been found necessary for tumour 
dissemination in an genetically induced cancer model [209, 210]. The enzyme is apart 
of cell membrane, which enables it to be a focal point for enzyme activity at the edges 
of podosomes and invadopodia [211, 212]. The extracellular part of the enzyme, 
harbouring the active site, can be shedded [213]. The enzyme can also be shuttled 
inwards via the actin filament, accumulate in centrosomal compartment and cleave 
pericentrin [214-216]. Pericentrin is an integral component of the centrosome that 
serves as a multifunctional scaffold for anchoring numerous proteins and protein 
complexes, and is likely important to normal functioning of the centrosomes [217]. 
The cleavage of pericentrin by MMP-14 is suggested to cause chromosomal 
instability, aneuploidy and subsequent tumorigenicity [214-216]   
 
1.6.4 M13 the Neprilysin family 
Neprilysin is a mammalian cell surface ecto-metallopeptidase that belongs to the MA 
clan, and also serves as the prototype for the M13 protein family [218, 219]. The 
human family currently consist of around 8 known members (NEP-1, NEP-2, ECE-1, 
ECE-2, PEX, XCE, DINE, KELL), and Except for ECE-1, all members of this family 
have first been discovered through their sequence homology with NEP and thereafter 
found to be catalysts [219]. The neprilysin family are interesting drug targets because 
of their involvement in pathologies [220-246], but also have other important functions 
[247]. Neprilysin can act on enkephalin [248], which are endorphins as they bind to 
the body’s opioid receptors, and enkephalinases are thus potential analgesic drug 
targets. The family has also many other substrates [249]. The protein database 
contained in august 2010 several structures of individual neprilysin family members 
that can be instrumental for further modeling studies, and therefore are examined 
here. There are seven entries in the PBD-database for neprilysin (entries; 2QPJ, 
2YVC, 1Y8J, 1R1H, 1R1I, 1R1J, 1DMT) with a resolution of 1.95 – 2.60 Å. All, 
except 1Y8J, includes a co-crystallized inhibitor among other phosphoramidon. There 
is so far only a single structure for human ECE-1, complexed with phosphoramidon, 





2. Pathological roles for MePs 
Enzymes, as biocatalysts, do work together to establish and maintain homeostasis in a 
living organism [250]. There are several control mechanisms that secure that 
individual enzyme are not over-active or under-active (thesis-chapters 1.61 and 4.4.2). 
Enzymes not properly regulated will build-up (if over-active) product molecules or 
accumulate substrate (if under-active), and the organisms dependent on the enzyme 
will divert from the normal homeostasis. The organisms will now show symptoms and 
signs of disease. The study of a disease looking into mechanism and processes that are 
dys-regulated is referred to as pathogenesis. It is important to note that dys-regulation 
of a given enzyme can form basis for different types of diseases (thesis chapter 1.6), 
but they can also work together to promote a disease. This chapter will focus on tumor 
metastasis and bacterial invasion and sepsis. Extracellular matrix degradation and 
blood vessel regulation are vital steps that are explored in more depth.  
   
 
2.1 Tumor metastasis 
The process where cancer cells spread from the primary tumour and form secondary 
tumours in another organ is referred to as metastasis [251]. In contrast to the primary 
tumour, that often can be surgically removed, secondary tumours are harder to 
eradicate surgically and/or by localised irradiation. Metastasis is therefore the 
principle cause of death for most cancer patients [252, 253]. The metastatic process is 
a multistep process [253], as illustrated in Figure 10, and each step in this process is 
tightly regulated. Initially, the metastatic cancer cells must be able to detach from the 




Figur 10: Illustration showing different steps in tumour metastasis. The illustration was found 
online (http://molpath.ucsd.edu/faculty/Yang.shtml). Permission of used was granted by 
associate professor Yang Jing, University of California, San Diego.    
 
Vital in this invasion process is the down regulation of adhesion molecules that tether 
the cancer cell to its neighbours. Furthermore, the cells must cross the basal lamina 
and the endothelial lining and penetrate into the blood or lymphatic vessel. In the 
circulation the cancer cells will survive for shorter or longer periods before they enter 
a microenvironment expressing the corresponding adhesion molecules, and then the 
opposite sequence of reactions can take place (extravasations). The cell penetrates the 
vessel wall and establishes a tumour in the new organ by proliferation. Both the 
escape from the primary tumour and colonisation of the remote site are complex 
processes and are crucial for metastases being referred to as an inefficient process. 
Only a very low amount of the tumour cells detaching from the primary tumour are 
supposed to form a metastatic lesion [254]. Metastasis is therefore a complicated 










2.2 Bacterial invasion and sepsis 
Bacteria invade body parts or tissues to secure self-sustainment or for improving 
living conditions causing local tissue injury and potentially disease [255, 256]. 
Helping agents such as enzymes and their substrate products are called virulence 
factors [257]. Numerous metalloenzymes aid the bacteria in this process and they may 
be recruited for direct or indirect degradation of connective tissue (thesis-chapters 2.3 
and 1.6.2). Pseudomonas aeuruginosa is for instance an opportunistic pathogen that 
can cause fatal infection in susceptible hosts [258]. Pseudomonas damages the host 
tissue directly and is also able to increase the mucus viscosity to make it less elastic 
and less transportable [259]. Adhesins enables the bacterium to adhere among other to 
host cells and colonize lung or wounded areas [256]. Like many other human 
pathogens, the microbe can inject toxic proteins directly from its own cytoplasm into 
the cytoplasm belonging to a host cell [260]. Pseudolysin is probably responsible for 
the destruction of arterial elastic laminae in the vasculitis observed in cases of 
Pseudomonas septicaemia [261]. Septicaemia is when viable bacteria enters into the 
blood system, and is commonly referred to as blood poisoning. The presence of a 
pathogen, such as bacteria, may provoke a systemic inflammatory response 
throughout the body, which is known as sepsis [262, 263]. Although this is a systemic 
response, it might be triggered by local presence of pathogens in the blood, urine, 
lungs, skin, or other tissues. Self-preservation is then also mediated by interfering 
with the hosts defence mechanisms. Pseudolysin and several other proteases from 
different pathogenic bacteria have been found to cleave plasma proteins such as 
immunoglobulins [264-266], complements factors [267, 268] and cytokines that are 
immunactive. The effect on the host cells are also up-regulation of cytokines and 
chemokines, affected cytoskeleton as well as other signal glitches rendering the 
immune cell unable to move towards and engulf bacteria. Severe sepsis is the 
accumulation of negative effects from the systemic inflammatory response, the 






2.3 Extracellular Matrix Degradation 
Cells in the body are surrounded by a thick layer of different macromolecules called 
the extracellular matrix (ECM) [269]. The ECM includes the interstitial matrix and 
the basement membrane in addition to defining the local environment of individual or 
communities of cells [269]. This matrix is a composed of diverse types of molecules 
outside the cells acting as a compression buffer against various stresses imposed on 
cells, connecting cells and functions as a reservoir for signalling molecules. The 
matrix itself is compost of proteoglycans (heparin sulphate, chondroitin sulphate and 
keratin sulphate), non-proteoglycan polysaccharide (hylauronic acid), fibers (collagen 
and elastin) and also fibronectin and laminin [270]. Extracellular matrix turn-over is 
however needed both in normal homeostasis and pathologies necessitating recruitment 
of proteolytic enzymes for this job. Traditionally the MMPs are recognized as ECM 
re-modelling enzyme, and some claim that they collectively cleave everything in the 
ECM, but ECM re-modelling is not performed by these enzymes alone [63, 270]. 
Hydrolysis of elastic fibers and other components of the ECM likely occur via both 
extracellular and intracellular means [63]. Altered regulation of these enzymes and 
subsequent remodelling of the ECM are hallmarks of several pathologies [271-273]. 
Many signalling molecules, previously tethered to the ECM, are also released and 
activated in these processes, while product fragments from the partial degradation of 
extracellular matrix components, recently termed Matrikines, can also become active 
transmitters of signals in close-by cells [274-279]. The weakened infrastructure, after 
ECM degradation, enables cells to migrate from their normal environment, for 
instance in cancer metastasis, as well as gain entry to blood and lymphatic system by 
breaching through basement membranes lining these organs. The extracellular 
fragments have been shown to act as chemotactic agents [280, 281], change cell 
behaviour [282] and affect host interaction for invading microbes and tumours. Most 
bacterial proteinases have a weak degradative activity against collagen, and bacteria 
might recruit collagenases from the host [283]. Fibroblasts are found locally at these 
sites already before infection, while cells such as neutrophiles and macrophages are 
recruited when bacteria are present. These cells secret several enzymes such as 
proMMP-8, proMMP-1 and proMMP-9. MMP-8 and MMP-1 cleave native triple 
helical type I collagen producing fragments that can denature and subsequently be 
cleaved by MMP-9 [283]. These MMPs were purified from different cell-types and 
their activation both by different bacterial proteinases and homologues from different 
bacterial species was examined [283]. Their results indicated that vibrio proteinase 
and pseudolysin showed strong activation of proMMP-9, and highlighted a potential 
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mechanism were bacterial enzymes can indirectly create ECM destruction and tissue 
damage by affecting host enzymes.  
 
2.4 Blood-vessel regulation  
The blood vessels are tubes that transport blood around in the different parts of the 
body [284]. The blood vessel diameter is mostly regulated by contraction or relaxation 
of the smooth muscle tissue in around the vessel [285]. The tissue responds to several 
factors that are broadly divided into vasodilators or vasoconstrictors [286]. The 
vasodilators decrease contraction in this tissue causing increased vessel diameter and 
increased flow of blood as the resistance or blood pressure decreases. Sympatic nerves 
or surrounding endothelial cells can regulate the vessel by transmitting paracrine 
signals onto the tissue [287-289]. Bradykinin (BK) is a nine amino acid long peptide 
belonging to the kinin group[290]. This peptide causes among other blood vessels to 
dilate [291]. BK is thought to act as a local janus-faced hormone, exerting both 
unwanted- and beneficial physiological effects [291]. This fact makes it´s regulation 
by local kininases, enzymes cleaving kinins, in the blood or on the endothelial cells 
important to understand. BK is in the body first generated from cleavage of 
kininogens by a serine protease named Kallikrein. BK can then activate B2 receptors 
leading for instance to VGF production. Several zinc-metalloproteases from separate 
families are capable of converting Bradykinin into inactive metabolites. Des-Arg9-BK 
functions as an activating ligand for B1 type receptor, and can be metabolised further 
by ACE and APP. ECE-1 cleaves bradykinin, and also produce a vasoconstrictor, 
endothelin, and therefore the turnover of bradykinin to inactive metabolites instigates 
a synergistic vasoconstricting effect. Pseudomonas a. has also been found to cause a 
deregulation of the bradykinin-pathway that subsequently leads to improved 
dissemination into the blood system [292, 293]. The first authors proposed that this 
action was due to the dilatory actions of Bradykinin and that the induced vessel 
leakage may serve as entry port for the bacteria into the blood network. Other bacteria 






3. Drug-aided treatment 
The body tries to control any changes in it natural homeostasis induced by a foreign 
intruder, for instance aided by the innate and adaptive immune defence [296-298], but 
might be unable to do so and outside help in the form of drug intervention might be 
necessary [299]. The simplest philosophy in drug targeting is that there should be one 
factor that causes or greatly contributes to the disease of interest, which then can be 
targeted [300], which in many cases is an over-simplified assumption [301]. Once a 
factor, such as an enzyme, is found promoting a process, which is enhanced in the 
disease, intervention aims to interrupt the continued promotion by the enzyme to this 
process. This means not to kill the process entirely, but more killing the excess work 
of the enzyme leading to disease, which stated differently; is adjusting the 
homeostasis back to normal. The body might be able to reverse the effects caused by 
the enzyme, but killing the process will not automatically reverse the damages already 
caused by the enzyme target. Time of intervention then becomes of importance. It is 
useful to learn from studies looking into pathogenesis in order to find single factors 
that contribute more than others in a malignant process. MePs are diverse governing 
global processes (such as cancer invasion), small specific processes and are present in 
normal as well as pathological environments (thesis-chapter 1.6). MePs are check-
points for potential intervention [302], and some have been attempted targeted for 
more than 50 years [51, 303]. The targeting can be direct interaction with the enzyme 
or targeting the regulation of the enzyme [51]. Problems in finding drugs that can be 
marketed indicates that it exist barriers that needs to be over-come or by-passed 
before we have useable drugs [304]. Developing working animal models replicating 
the disease, and even finding the correct disease to target can be difficult for MePs 
[305]. Branches of systems biology are devoted to mapping substrate preferences for 
MePs, most notably the bigger “degradomics” profiling of the MMPs [166, 306], 
while others attempt to categorize phenotypic effects of drugs [147, 307-310]. Such 
studies increase understanding of the targets roles in that environment and may give 
clues to structural adaptations towards selected substrates. Databases of phenotypic 
effects of drugs can also be used to give clues about potential off-target enzyme 
partners, and systemise similar side effects of unrelated drugs [147, 307]. These 
databases might be able to propose additional targets for existing drugs, often 
implicated in different therapeutic categories. They are also particularly useful in 
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those cases where side-effects are due to inhibition of structurally distant enzymes, 
because these would normally need more experimental indications for us to believe in. 
Drugs with similar binding profiles tend to cause similar side-effects [147, 307]. 
Finding one enzyme promoting a process, which is enhanced in the disease, the aim of 
an inhibitor is to discontinue the ongoing promotion by the enzyme to this process. In 
a given disease, one enzyme/target can contribute in different ways. Processes that 
govern cancer (or bacterial invasion) can be either found in several cancers or be 
specific for one cancer-type. It is naturally difficult to predict and anticipate adverse 
effects without a complete knowledge of the substrates and regulation mechanisms of 
the target.  
 
3.1 M4  
Thermolysin itself seems not to be implicated in any human disease as the bacteria 
that produces it lives in a very thermophilic environment. However, thermolysin has 
acted as a model for other thermolysin-like enzymes that are causative of human 
disease (see thesis 1.6.2 and chapter on thermolysin). Secreted virulence factors from 
pathogens such as Legionella [311], Listeria, Clostridium, Staphylococcus, 
Pseudomonas and Vibrio belong to the M4 protein family [261]. Pseudomonas a. is 
considered a dangerous pathogen as it is naturally resistant to many classical 
antibiotics [312]. Antibiotic resistance is an old phenomena [313], but use and misuse 
of antibiotics might have contributed to creation of a niche for tolerant pathogens 
[314, 315]. Currently, antibiotics target a small selection of global processes essential 
for bacterial survival, and therefore a process-change induced to tolerate one drug 
would potentially impair the effect of other drugs too. Multidrug-resistant pathogens 
(MDRP) are associated with increased treatment expenses and might lead to poorer 
outcome [316-319]. Pharmaceutical companies has over a time period not focused in 
finding and developing new drugs increasing further the need to address MDR and 
exploration of novel targets [320-323]. Therapeutic inhibition of several M4 enzymes 







The M10A enzymes are collectively and individually implicated in many diseases 
[324], and for this reason are seen as drug targets [325, 326]. Drug development 
programs were launched in the 1980-90s mostly focusing on metastasis and 
angiogenesis [327]. Trials on drugs were discontinued mainly because of induced 
side-effects [327, 328]. The number of marketed M10A drugs today can be counted 
on a single hand, which is a low number compared to the amounts of inhibitors 
currently available [304]. As it seems that MMPs touch almost every aspect of 
mammalian biology, it is natural that they themselves have pro-disease as well as anti-
disease effects, which necitates that MMPs implicated in a disease are subdivided into 
anti-target and target respectively [329, 330]. An anti-target in one disease might be a 
target in another disease. Naturally, the drug needs to hit a single or several targets, 
while have no or little interactions with anti-targets. Studies then need to validate what 
are targets and anti-targets. A process can be extracted in order to see how each 
enzyme contributes.  The vast amount (and still increasing) number of substrates for 
each enzyme, with partial redundancy (two enzymes share the same substrate) not 
only create difficulties in both designing a drug but also problems with how, where 
and when to administer a MMP-targeting drug.  
 
3.3 M13   
The M13 enzymes have been attempted targeted in several diseases [331], mostly 
connected somehow to the blood environment and regulation [58, 332-338]. In some 
of the diseases, the target has been located in the brain, and therefore the blood-brain 
barrier needed to be crossed [339]. Several of the inhibitors with nanomolar affinities 
for NEP and APN have been shown to completely inhibit enkephalin degradation in 
vitro and in vivo [340-342]. The location of the target(s) forces the drugs to cross the 
blood-brain barrier, and several of the early inhibitors have a high water-solubility 
preventing them from reaching their target(s). Highly potent and selective inhibitors 
targeting each enzyme were covalently linked by a disulfide bond in order to expose 
their lipohilic nature and allow them to cross this barrier [339]. The bond uniting them 
is relatively stabile in plasma, but is rapidly degraded in the brain environment [339]. 
Targeting of this family is not only inhibition, but also activation [343]. Attention has 
been given to the “Endothelin axis”, which then aim to target one or several of the 
components found collaborating in cell signalling [338]. In cardiovascular disease, 
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there has been an interest of making inhibitors with affinity towards two or three 
enzymes [344-350]. Dual targeting of NEP-1 and ECE-1 has been shown to have 
synergistic effect on blood pressure regulation [339]. One of the reasons for this is 
probably that ECE-1 is inhibited from producing the vasoconstrictor (Endothelin) and 
also from degrading the vasodilator Bradykinin. NEP-1 is also inhibited from 
degrading Bradykinin together with other vasodilators (Endorphin-1 and -2). An 
undesired effect in targeting NEP-1 is that the enzyme normally degrades endothelin 
and acts as an antagonist of ECE-1 regarding this substrate.  
 
4. Inhibition 
Enzyme inhibition is an important part of understanding any enzyme [351]. Here, a 
reaction between a molecule and an enzyme that blocks the action of the enzyme, 
either temporarily or permanently is studied. This process occurs in the natural world 
all the time, and it has a number of applications [351]. The molecule itself is called an 
inhibitor, and can be used as a drug. Here it is important to note the difference 
between a “drug” and an “inhibitor” [352]. The drug can be an inhibitor that has been 
more extensively tested in several models, and is safe enough to use in a given disease 
treatment regime either on plants, humans or other animals. So, many inhibitors are 
characterised in the intention of developing it into a drug [353]. However, an inhibitor 
might be very potent, meaning that it effectively reduces the enzyme activity at low 
concentration, but may be unfit to use as a drug. These inhibitors are still useful in 
biology studies. Specific inhibitors can for instance be administered to cells in order 
to turn off or modulate signalling pathways as long as they are tolerated by the cells. 
Metabolites in the Krebs cycle (or any other metabolic pathway) were also better 
understood by administering inhibitors of the different enzymes in the pathway [354]. 
The continued developments of reductionist models (such as cell cultures and FRET 
assays) as well as interest in isolating metabolites from other species clearly advocate 
applications for inhibitors in studying enzymes in a biological context [355, 356]. 
They can also be used as control mechanisms in synthesis processes dependent on 
enzymes [357]. Enzymes can also be seen on a mechanistic level using inhibitors to 
explore surfaces, charge distributions or investigation into how collisions and 
catalysis of a substrate in a solvent occurs, which might have unknown or 
unrecognized applications. The active site of several MePs and other ligand binding 
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pockets are ideally suited for high-affinity interactions with drug-like inhibitors [358].  
 
4.1 Activity towards isolated enzymes  
The potential inhibition of an enzyme by small molecular compounds can be explored 
in systems with isolated enzymes. Among the benefits of using isolated enzymes is 
that it might be easier to investigate casualities that might otherwise be harder to 
isolate and study in cell or tissue environments that are more complex [359]. In return 
it might be that findings on isolated enzymes are not applicable and inferable to more 
complex systems because important factors are eliminated [359]. It is also important 
to note that enzymes inside cells are often found in highly concentrated multi-protein 
plasma environments. An enzyme inhibition assay can be dissected into; an enzyme 
component, the buffer environment, the inhibitor and a method for detection and 
evaluating inhibition. The enzymes themselves are sometimes hard to obtain in the 
needed quantities [360]. Therefore, biological systems that can synthesise a protein 
encoded by a gene of interest are needed. This process is called engineered protein 
expression, and the protein is named a recombinant protein. Hosts, with few 
exceptions, will translate the codons into the correct amino acids making the native 
primary protein sequence [361]. Enzymes provided by the host perform the 
modifications of the protein, and non-functional proteins can arise if the host lack 
these enzymes, or read the instructions in the primary sequence differently from the 
native host [362]. This is something we should have in mind since most of our studied 
enzymes are recombinant mammalian enzymes produced and isolated from among 
other bacterial hosts (manuscript 1: methods and material section). Membrane-
tethered enzymes are particularly difficult to study as isolated enzymes without the 
ability to truncate and remove the catalytic- site from the overall body of the enzyme, 
which would normally incorporate the protein in the lipid-bilayer of the cell 
membrane [363-365]. The amino acid sections that allow the protein to traverse the 
lipid-bilayer is hydrophobic, and might create solubility problems [364]. The activity 
of isolated enzymes can be measured in FRET-based, fluorescence resonance energy 
transfer assays [366]. Inhibition by a putative ligand is usually inferred from 
interruption of enzyme activity in an assay such as a FRET-based assay [366, 367]. 
Here, energy is transferred between two chromophores [366]. A donor chromophore 
may transfer energy to an acceptor chromophore (in proximity, typically less than 
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10 nm) through non-radioactive dipole-dipole coupling. The donor is excited by an 
external light energy source, and ideally little energy should be transferred out of the 
system for us to detect in the energy transfer onto the acceptor chromophore. In an 
enzyme assay, the two chromophores can be linked to a protein sequence that is 
recognized by one or several proteases [366, 368, 369]. The length of the protein 
sequence and incorporation of several elements recognized by different enzymes 
allows the same synthetic substrate to be used to assay enzymes of different families 
and classes [368]. Proteolytic enzymes that recognize this sequence will cleave and 
separate the two chromophores. Two molecules are now produced creating distance 
between the donor-acceptor chromophore-pair, and the energy that was transferred to 
the acceptor can be transferred to a detector instead. The energy measures will be 
proportional to the number of product molecules generated, which is related to the 
amount of active enzyme. The activity of the ligand will be connected to its ability to 
interrupt in this process [369].   
    
4.2 Inhibition types 
Inhibitor molecules act on enzymes in different ways [370, 371]. Most often inhibitors 
that covalently attaches to the enzyme are irreversible, while inhibitors that mediate 
interactions through hydrophobic and ionic bonds can associate or dissociate 
reversibly. However, there are grey areas where an inhibitor associates so hard, and 
hardy dissociates, that it is irreversible, but is still viewed as binding reversibly 
(although tightly), and there are cases where covalent-linkages inactivating an enzyme 
are removed thus restoring enzyme activity. The stability of covalent bonds is relative, 
and esters are among the least stable covalent bonds in aqueous solution. There are 
four main types of inhibition; competitive, non-competitive (or mixed), uncompetitive 






Figure 11: Graphs illustrating competitive (first left), mixed or non-competitive inhibition 
(middle) and uncompetitive inhibition (far right). The graphs are also called lineweaver-Burke 
plots, were the x-axis is 1/[S] and Y-axis is 1 /V0. [I]x are inhibitor concentrations were [I]0 < 
[I]1 < [I]2.   
 
The signpost of competitive inhibition is that inhibition effect is lowered or removed 
by addition of more substrate (figure 11). Often this is because they compete for 
occupation of the same binding site, but also allosteric binding to distant sites might 
lead to enzyme changes so that once one is bound, that excludes the other from 
binding. Increased concentration of substrate (low 1/[S]), on a lineweaver-Burke plot, 
will null the effect of inhibition and lines for enzyme activity with or without inhibitor 
all intersect at the Y-axis. This also implies that the inhibitor only binds to one form, 
free enzyme, and not substrate-bound enzyme. The signpost of non-competitive 
inhibition is that inhibition effect is not lowered or removed by addition of more 
substrate, and that the inhibitor binds with same strength to free or substrate-bound 
enzyme (or that substrate binds equally well to free or inhibitor-bound enzyme). 
Mixed inhibition is signified by an inhibitor that binds to both enzyme forms, albeit 
with different affinities. These two mechanisms have lines intersecting on the x-axis 
(non-competitive) or in second quadrant (mixed) on a lineweaver-Burke plot (figure 
12). Uncompetitive means that the inhibitor will only bind to an enzyme-substrate 





Figure 12: Graphs of non-competitive and mixed inhibition (left, right). These are 
lineweaver-Burke plots (X-axis = 1/[S], Y-axis = 1/Vo) [I]x are inhibitor concentrations were 
[I]0 < [I]1 < [I]2.   
 
4.3 Interpretation of Inhibition 
The potency of a putative inhibitor needs to be evaluated quantitatively somehow. 
Naturally this is often related to the wanted trait of the compound – inhibition of 
enzyme function. Different amounts of an inhibitor can be added to an enzyme assay 
creating a dose-response curve. The half maximal inhibitory concentration (IC50) is 
then the amount of a compound such that the enzyme activity is lowered by half 
[372]. This value is found with the substrate concentration as a parameter (fixed), 
while the inhibitor concentration is varied (see figure 17), and is a much used value 
for comparing small or larger sets of putative inhibitors for an enzyme. The IC50-value 
is more accurately determined the more [I] tested, and it is good practice to include 
[I]-values both above (reducing the activity by more than half) and below (reducing 
the activity by less than half) than the anticipated IC50-value. The IC50-value, for a 
non-tight-binding inhibitor, is dependent on the [S] in the experiment, and is an 
affinity measure, assuming that the inhibitor binds to enzyme, but can tell nothing 
about what the inhibitor has affinity towards, meaning if either free or bound enzyme 
(or both) is targeted by the inhibitor. Another numerical value describing inhibition, 
KI, is the equilibrium constant for the dissociation of the E-I complex. Half of the 
amount of E-I complexes are found dissociated when [I] = KI, and is therefore an 
approximation of the affinity between these components. The value is found by 
making variables of both [S] and [I], and can then be thought of as collecting IC50-
values at different [S]. The relationship between IC50 and KI can be calculated, but is 
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dependent on the inhibition type to explain the cause of inhibition – if one enzyme 
form (either free or bound enzyme) or two enzyme forms (both free and bound 
enzyme forms) are targeted by the inhibitor. The IC50 will move towards been equal to 
KI for small values of [S], twice of the KI when [S] = Km and increase for larger 
values of [S], while the opposite is true for an uncompetitive inhibitor.  
 
11. IC50 = Ki • (1+[S]/Km) 
12. IC50 = ([S] + Km)/((Km/Ki) + ([S]/K’i)) 
 
Equations 11, 12: IC50-calculations using equilibrium constants. Equation 11 is for 
competitive inhibitors, while equation 12 is for mixed inhibitors. IC50 is the inhibition 
constant where the activity is reduced by 50 %, Ki is the equilibrium constant between 
inhibitor and free enzyme, [S] is substrate concentration, Km is the Michaelis-Menten 
constant, K’I is the equilibrium constant between inhibitor and enzyme-substrate 
complex.    
 
4.4 Exploring binding surfaces 
Substrate-binding precedes catalysis, and the low energy involved in stabilisation of 
an E-S complex, and also the fact that the substrate may not be perfectly adapted for 
the enzyme (rather than the transition state), opts for possibilities of interruption of 
this step. An inhibitor can create a stable complex with the enzyme, much like the 
lock and key analogy. Potential targeting areas can be inferred from the structure on 
enzymes alone or from interfaces between enzymes and other ligands (presented 
thesis-chapter 5.1.1). Enzyme-substrate complexes are very useful in this regards, but 
are difficult to experimentally determine [373]. The crystal structure of an IDE-
Bradykinin complex (PDB-entry: 3CWW) draws some attention in this thesis as the 
fluorometric assay utilized is a FRET coupled site-directed sequence resembling 
bradykinin [374]. The amino acids involved in the recognition of this substrate in the 
co-crystal can then be natural amino acid-interaction partners for synthetic ligands. 
Knowledge can also be extrapolated onto similar enzymes as insulysin share 
similarities with other metalloproteases [56]. Binding surfaces between inhibitors and 
enzymes are also relevant in this regards [375]. A separation of native versus natural 
inhibitors can be made. Native inhibitors can be seen as those produced by the system 
and are locally available to regulate the activity of “in vivo”-targets. Natural inhibitors 
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are native inhibitors of some systems, but may be extracted from this environment and 
introduced to inhibit enzymes of other systems which it is not native to. The large size 
of interacting surfaces might give clues to surface targets, and it also gives 
information on structural adaptations brought forwards by evolution that scientists can 
copy or improve by smaller-molecular ligands. In the following, some of the most 
important natural/native inhibitors will be presented for the enzymes worked on in 
this thesis. It is important to note that some of the inhibitors act globally on many 
enzymes family (for instance Phosphoramidon and α-Macroglobulin) while others are 
more specifically targeting one family or individual family members (for instance 
TIMPs). Larger inhibitors (including peptide-based) are very important as predecessor 
for small-molecular compounds, and is therefore included here as well. 
 
4.4.1 Phosphoramidon 
Phosphoramidon is a chemical compound derived from cultures of Streptomyces 
tanashiensis, which acts as a tight-binding but unselective inhibitor toward several 
MePs [376-379]. This compound potentially acted as a regulator of the hosts own 
MePs, but also as an antibiotic compound fighting off other microorganisms, and it 
has been influential for inhibitor design targeting similar proteins. Phosphoramidon 
has been co-crystallised with several family members in the MA clan with the same 
monodentate antagonisation of the catalytic zinc-ion by the inhibitor [380]. The 
inhibitor might then stabilise loops and parts of the protein scaffold so that 
crystallisation is possible. Phosphoramidon has also been used to down-regulate 
activity of phosphoramidon-sensitive peptidases in biological models to verify the 
contributions of such enzymes [303, 306].  
 
4.4.2 TIMPs 
Proteins of the TIMP, Tissue inhibitors of metalloproteinases, family act as native 
inhibitors of the MMPs [375, 381-387]. Four members are found so far, and these are 
often abundant in most tissues and body fluids. Overall topology differs considerably, 
in spite of 40 % sequence identity [388]. In diseases these are found down-regulated 
or show an altered ratio with its target. Restoring the normal balance has been a 
therapeutic strategy, but TIMPs can for instance also promote cancer initiation 
themselves. These proteins bind tight to their target, in the pM-range, and each of the 
TIMPs act unselectively on several MMPs. TIMPs can also be selective towards some 
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of their targets, and in the case of TIMP-2-mediated proMMP-2 activation give 
information about other protein-protein interaction surfaces [389]. Studying 
interactions between TIMPs and interacting protein partners can thereby reveal 
information about epitopes on the enzymes that can be target by other means (such as 
small-molecular inhibitors) [390, 391]. TIMPs can also be modified to gain selectivity 
and used as inhibitors [392, 393]. The N-terminal subdomain exhibits an OB-fold, and 
seems to be vital for the inhibitory actions of individual TIMPs towards their 
respective MMP-target [140, 375]. 
 
4.4.3 α-macroglobulin 
Alpha-2-Macroglobulin is a large plasma protein abundant in the blood [394]. The 
immature inhibitor has a bait region of about 35 amino acids, which includes several 
sequence-recognition sites of various enzymes. Proteolytic cleavage in the bait region 
induces a conformational change that entraps the endopeptidase [395]. In the blood, 
the resulting proteinase-α2M complex is in turn recognized by macrophage receptors 
and cleared from the system. The bait-region in this mechanism-based inhibitor has 
been manipulated by researchers attempting to create selectivity by manipulating 
numbers and sequences of cleavage sites. Interacting sites in the proteinase-α2M 
complex has also been studied and compared with similar natural mechanism-based 
inhibitors present in various tissues and environments as potential drug/inhibitor 
targeting sites [396, 397]. 
 
4.5 Small Molecular Ligands 
Small molecular ligands, which are often organic molecules, that binds to a protein or 
peptide and affecting their activity can have therapeutic value or other uses. Key 
interactions between protein-proteins (natural inhibitors) can be mimicked and 
potentially improved [398]. These molecules also might avoid being degraded, 
contrary to administered peptide or proteins, and prolong their availability in the body, 
avoid some side-effects (but potentially gain others). These might also be more cost 
effective and easier to model due to size and degree of complexity. Ligands can be 






4.5.1 The Active-site 
The active site can be said to be that part of an enzyme where substrates bind and 
undergo a chemical reaction. This will always include the catalytic triad, which are 
those amino acids that are involved in catalytic transformation. For enzymes that have 
many different substrates, and of very different sizes, it becomes a bit unclear what 
interacting sites constitutes apart of the active site and what are not. In the following, 
the active site will include the catalytic triad, the prosthetic zinc-ion as well as sub-
pockets.  The Zinc-ion with valence number two is an intermediate acid in Pearson’s 
Hard and Soft Acid and Bases, which preferentially binds to hard ligands [399, 400]. 
However, when held by three nitrogen donors from histidine-residues, the fourth 
coordination site on the tetrahedral Zinc favours softer ligands [399-401]. Strong 
interactions with the zinc-ion will create un-selectivity, while interacts with sub-
pockets gain selectivity. Ligands often have a ZBG (zinc-binding group) coupled to a 
backbone that will support interactions with sub-pockets [304]. Regarding the MMPs, 
the S1‘-subpocket have been seen as the pocket vital for substrate specificity [54, 
402], but this view is contemporary and might shift according to better understanding 
of all sub-pockets involvement in substrate-binding. Selective MMP-13 inhibitors that 
act non-competitively and non-chelating by positioning deep inside the S1’-pocket 
have been described [403], while similar inhibitors have been found and speculated to 
have similar binding-site. 
 
4.5.2 Hydroxamates 
Hydroxamates are essential growth factors, which functions mostly as iron-binders, 
named siderophores, aiding the microbe to scavenge essential iron from the exterior 
environment and transport it into the cell [404-407]. Hydroxamate-groups have 
therefore been incorporated in different antagonists targeting the active sites of 
metalloenzymes. The widespread use of hydroxamates in MMPIs is partly due to the 
fact that Hydroxamate- affinity columns was traditionally used in purification of 
MMPs [408, 409]. Comparative studies on compounds differing only in their ZBGs 
also indicated hydroxamic acids to have the best in vitro potencies toward members of 
this family [409]. Targeting MMP-3, the hydroxamate in isolation has been shown to 
have a Kd of 17 mM and an IC50 of 25 mM, indicating that a backbone with several 
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favourable interactions with the active site facilitates a further tight binding [409, 
410]. Batimastat and marimastat are two well-known MMPIs belonging to the 
succinic class of hydroxamate-based inhibitors [411]. These mostly differ in that 
marimastat is more bioavailable. Both of them had an inhibition in the nanomalor 
range, and batimastat was the first of this class to enter clinical trials. Batimastat had a 
poor bioavailability, and failed the clinical trials due to side effects such as muscular-
skeleton problems. The hydroxamates have been associated with toxicity as well 
[412]. Reverse Hydroxamate inhibitors have better pharmacokinetic properties than 




Figure 13: The illustration shows the atomic constituents of the hydroxamic acid (left) and 
the retro-hydroxamic acid (right). The illustration is made with ChemBioDraw Ultra version 
12.  
   
4.5.3 Non-Hydroxamates 
Inhibitors with a ZBG-group different from the hydroxamates, and 
retrohydroxamates, which targets the catalytic zinc-ion with polar or charged groups 
is often referred to as non-hydroxamates in the field of MePs inhibition [414, 415]. 
This group of inhibitors is diverse both in ZBG and overall scaffold making it hard to 
find statements that are valid for all cases. However, several of the non-hydroxamates 
have been investigated to address the two main problems associated with the majority 
of hydroxamates; specificity and bioavailability [416]. Specificity could sometimes be 
gained by weaker interaction with the catalytic zinc and with more importance put on 
interactions with sub-pockets and overall target topology. There are several examples 
of non-hydroxamates with a ZBG consisting of sulfhydryl, carboxylic, and 
phosphonic-moities [417]. PAC-1, and its derivates, and the isatin 1,2,3 triazoles are 
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also non-hydroxamates according to our own findings. Many of the ZBGs are inspired 
by natural inhibition mechanisms seen in molecular switches [416, 418-420] or from 
exploration into interfaces of native inhibitors and their targets [421-423] .  
   
4.5.4 Mechanism-based Inhibitors 
Mechanism-based inhibitors have been an idea in the wake of the promiscuous 
bidentate zinc-coordination seen in many inhibitors [424, 425]. There are different 
types of mechanisms that can be used to gain selectivity. One approach is to create a 
pro-drug that is inert and needs to be activated. The switch itself is often coupled to 
the enzyme-target or features in the local environment of the disease-cause so to 
potentially gain selectivity and potency. Features of the prodrug might also create 
better availability and/or might affect stability [426]. Partial cleavage of the pro-
inhibitor, which is the case for α-macroglobulin, can be an activating switch, but also 
other means can be used to activate the prodrug.  Some cancers are found to have 
elevated levels of reactive oxygen species (ROS), which then can be used to activate 
ROS-triggerable prodrugs targeting MMPs [427]. The inhibitor can also have 
chemical groups that react with the enzyme target, for instance by creating covalent 
bonds to residues that are essential for catalysis. One inhibitor, SB-3CT, acts as a 
selective inhibitor for the gelatinases [428]. The inhibitor binds slowly to the catalytic 
zinc-ion, mediated by non-covalent interactions with the enzyme [428-433]. The 
glutamate involved in catalysis then goes to nucleuphilic attack on the thiirane ring, 
which results in a covalent bond between the glutamate and the inhibitor and a 
sulphuric ion interacting with the catalytic zinc. Thiiranes were tested against their 
oxirane-counterparts, which replaces the sulphur-ion with oxygen, which did not have 
the same activity highlighting the importance of the sulphur-atom. Functional groups 
were added in order to combat solubility issues as well as better interaction with the 
deep S1’-pocket of MMP-2. The inhibitor could become a promising drug as it 
showed inhibition of MMP-9 in an animal study on transient focal ischemia, rescuing 
both Laminin from proteolysis and neuron from apoptosis [434] and also has an 







Regions outside the catalytic site that contribute with interacting surfaces for larger 
substrates, other catalytic functions or mediate other protein-protein dockings are 
interesting to target [436, 437]. On enzymes, these elements are often more 
individualised because they are subject to a different conservational pressure than the 
active site, and might be purposely different to allow for instance interactions with 
other sets of protein partners. The interest in exo-site is growing, and efforts are made 
gradually to understand which exosites are involved in what processes [436, 438-443], 
and mapping residues that then defines those exosites in these. Non-small-molecular-
inhibitors phosphonate coupled peptide transition state analogue, were more selective 
towards the gelatinases than other MMPs compared [444, 445], and it was proposed 
that the size of the inhibitor allowed it to interfere in exo-site dependent processes. 
P713 is a peptide with high identity with a segment of the human α1(I) pro-collagen 
sequence could inhibit the gelatinolytic process mediated by MMP-2 [446]. Seven 
compounds (out of ~17000) has also been suggested to interact with specific residues 
characteristic for MMP-13 hemopexin domain using a cheminformatics-based 
approaches including sequence comparisons in the hemopexin-region, virtual 
screening, docking and assessment of drug-like qualities [447]. These inhibitors 
remain to be tested in additional assays other that “in silico”-based. The authors also 
commented on that during their study the number of MMP sequences in the NCBI 
Entrez protein public database almost doubled, and that analysis of the sequences 
revealed that the number of residues unique to MMP-13 reduced from 34 to only 10, 












5. Free energy calculations 
A molecular system goes through chemical changes in an attempt to minimize its 
internal energy and to increase its entropy (chapter 9 and 10 [448]). The most 
important function attempting to describe such systems is Gibbs free energy equation. 
The free energy can be calculated from the equilibrium dissociation constant KI, 
which then approximates the affinity between enzyme and the inhibitor. For inhibitor 
design, this is valuable as it can be a theoretical approach for examining individual 
contributions in an E-I complex, or also compare smaller or larger sets of inhibitors 
before testing in the laboratory. There are many computational approaches that 
attempts on calculating free energies, which can be somewhat divided according to 
how many system variables are included and how complex they interpret these. 
Accuracy of the estimates naturally depends on what is included as part of the model. 
Theoretical protein systems are viewed as molecular mechanical systems, among 
other neglecting the spin contributions from electrons. This is an inherent 
simplification that is found in most of the systems available. MM approaches range in 
complexity, but clear boarders can not be drawn [449]. MM-PBSA, LIE and docking 
and scoring are examples of different MM approaches [449]. Accuracy of the 
estimates naturally depends on what is included as part of the model, and sometimes 
the approaches are finally tuned towards certain test-sets and thereby biased in their 
assessments. Still, Theoretical interpretation on ligand binding, like docking and 
scoring, may contribute with molecular insight into the binding process and are 
therefore implemented for instance in virtual screens or correlated with experimental 












5.1 Modelling the system 
It is important for us to understand what our model consists of and also more about 
the limitations and potential errors in predictions that might arise. Many times one 
purposely simplify the model so to make it easier to accommodate screening 
processes with accepted thresholds for errors, while other times there are errors 
associated with the methods that are so hard to avoid that they are accepted. The 
model can be limited to only the enzyme and ligand, or include to varying degrees 
both interactions with the surrounding (solvation) and also dynamic movements. The 
latter are also dependent on the protein structures available. 
 
5.1.1 Protein structures 
For many proteins the structures have been experimentally determined, mostly using 
NMR or X-ray crystallisation methods, and efforts are made to accelerate the 
determination rate of protein structure [453, 454]. The architectural design of the 
protein is then found as coordinates of atoms, which can be deposited in databases. 
Inhibitors can be co-crystallised with the target, and true positions under those 
experimental conditions can then be found. Such co-crystals form the basis for 
knowledge-based inhibitor design [455]. These co-crystals might have crystal-induced 
artifacts that might influence the scoring parameterisation and subsequent 
performance [456, 457]. Theoretical assumptions on placement of inhibitor can also 
be done on a determined target structure as well [455]. Then, the theoretical 
calculations are very dependent on the coordinates of the structure, which can be 
referred to as structure-based inhibitor design. Theoretical calculations might also 
impose changes on the experimentally determined structure, and it is therefore 
important to bear these changes in mind when assessing the model itself and its 
predictive power. Going some steps backwards, we note that purified high-
concentrated protein is packed together in an orderly fashion in X-ray crystallisation 
methods, which may create artifacts. The x-rays may impact on the structure during 
data collection [458-460]. The method attempts on creating an image of the protein 
using low temperatures limiting conformational sampling and potential protein 
instability [457]. There are some attempts on using higher temperatures in the x-ray 
collection phase so to get more information on conformational sampling [461]. 
Resolution is also a varying factor, where some structures have been found with high 
resolution and other with low. The resolution can be improved in the theoretical 
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model, by among other utilising assumptions on expected bond lengths and 
connecting atom-partners. Environmental conditions such as salt and pH might be 
higher or lower than normal among other to stabilise the protein, for instance proteins 
with self-catalytic actions might be kept inactive this way. The state of the protein 
under other pHs can be theoretically modelled thus altering properties of the 
experimental structure. Often static assumptions on Ka-values of amino acids are used 
in this process potentially neglecting imposed alterations by the surrounding amino 
acids on some residues Ka-values. Structures of the target enzyme co-crystallised with 
another inhibitor has many uses. By itself, the inhibitor can point to structural 
adaptations to mimic, but it can also be replaced with another inhibitor of interest. 
Then, it is important to bear in mind that the structure might have been structurally 
moulded towards the co-crystallised inhibitor and may be structurally biased towards 
similar inhibitor-scaffolds. 
 
5.1.2 Force fields 
The motions of electrons and nuclei in a molecular system are described by the 
Schrødinger equation (chapter 7 [462]). In molecular modelling (MM), a force field 
can then be viewed as an attempt to solve this equation for a given molecular system 
empirically with experimental data and approximations. A quantum mechanical (QM) 
solution in contrast would rely on theoretical calculations only. The Born-
Oppenheimer approximation, detaching the movement of electrons from the nuclei as 
they have a much smaller mass and higher velocities, treats the nucleus as an 
unmoving object while only considering the single electrons effect on the other 
electrons. This assumption allows a transition from QM into molecular mechanics (in 
between we find “ab initio” QM and Semi-Empirical QM). MM moves toward 
Newtonian physics viewing molecules as a collection of masses centred at the nuclei 
(atoms) that are connected by springs (bonds). The molecular mechanics energy 
(EMM) is expressed as the sum of different energy contributions seen in equations 13-







13. EMM = Elocal + ENonlocal (+ EMiscelleanous) 
14. Elocal = EBond + EAngle + Edihedral angle 
15. ENonlocal = EvdW + Ecc 
 
Equations 13-15: Force field equations (chapter 2 [463]). EMM is the molecular mechanics 
(force field) approximated solution to the Schrødinger equation. Local energies (Elocal) are 
attributed to formation of covalent bonds (EBond), the angle between 3 given atoms (EAngle) and 
from the dihedral angle (Edihedral angle). The nonlocal energies describes electrostatic (Ecc, 
columbic contributions) and van der Waals interactions (EvdW). EMiscelleanous includes 
parameters to adjust for deviations between theoretical values and experimental findings.    
 
 
The nonlocal energies describes electrostatic (columbic contributions) and van der 
Waals interactions. These forces can have effects exceeding the local ones. However, 
they can have tremendous local effects too, that needs to be implemented either in the 
local or nonlocal energy term. Due to among other their far reaching nature, the 
nonlocal energies are the most difficult to account well for in a MM simulation. MM 
needs information gathered from experimentally derived crystal structures, NMR and 
vibration and microwave spectroscopy. At present, there are many different algorithms 
for generating a force field, which can have different parameters that affect the Elocal 
and ENonlocal. The different algorithms can implement quantum mechanical 
considerations to different degree, and they can have other applications to account for 













5.1.3 Energy minimisation 
Molecules can adopt many distinct structural arrangements, which correspond to 
different energies (chapter 3 [463], chapter 10 [462]). These energies can be 
graphically represented as energy landscapes, and valleys would then represent 
minimum values. Minimums will have smaller energies relative to their nabours 
(local), but still might not be the overall minimum (global). Molecules would more 
often adopt the conformations corresponding to minimums as these are more stable. 
Energy minimisation of a molecule is usually performed to arrive at these more 
populated states in the landscape, and thereby the quality of the model in subsequent 
work is improved (chapter 3 [463], chapter 10 [462]). The force field expression 
(EMM), remembering that we might have approximated or neglected entropy effects, is 
what is minimized. Small errors in the bond length, affecting Ebond, will contribute the 
most to errors in EMM. For the computer, performing a minimization is not a trivial 
matter. The methods can be divided into first-order, only requiring an expression for 
the energy, or second-order, requiring an energy expression and its derivatives. 
Steepest descent and conjugate gradients belong to the first – order category. In 
steepest descent the derivate of the energy function guides moving towards energy 
minimums. The derivate, will be defined as the slope of the energy function. The 
longest steps are taken farther away from the minimum, distance from x0 to x1 longer 
than x1 to x2, so it slows down towards the minimum. Problems arise in circumstances 
where the derivate function moved towards zero because the energy function flattens 
out without been a minimum. In the three dimensional energy landscape, searches 
might not follow a strait line but instead move shift direction to cover more area in the 
landscape. For the second-derivate methods, such as Newton Raphson, the first 
derivate of the energy function will dictate the direction of the vector, while the 
second-derivate gives the curvature of the direction vector (chapter 3 [463], chapter 
10 [462]). The second-derivate methods are less reliable far from minimums while 
faster and more reliable closer to a minimum. Effort is made to combine the first and 
second order methods because of their opposing strengths. There are different 
considerations a modeller should bear in mind when it comes to the minimization 
process. The process can be initiated with different starter energies to avoid that the 
algorithm is stranded in a point that might not represent a minimum. Different 





The strength of the direct interactions between Ligand and Enzyme are often over-
rated due to the difficulties with assigning proper charges onto the metal-ion [464]. 
The net charge of the metal might be higher in the model since it is difficult to 
correctly assess how the charge might be affected by the protein environment as well 
as distributed onto nearby amino acids. Quantum mechanical approaches on the 
interacting site might be a way to address this, but come at a computational cost [465]. 
 
5.1.5 Water-problems 
Water molecules might for instance actively take part in a catalytic mechanism [464-
466], and thus their removal is detrimental if the structure will be used in catalytic 
mechanism simulation. The same might be for water molecules kept and 
hydrogenated. The size of the enzyme most often creates a cavity with a unique 
environment. Hydration of non-polar groups and van der Waals interactions between 
the same groups generally defines the hydrophobic interactions. Destabilisation of 
protein structure is associated with a negative free energy and is a result of hydration 
of polar and aromatic groups. The negative free energy from hydration of polar and 
aromatic residues is much higher than the positive Gibbs free energy from hydration 
of nonpolar groups and the net hydration effect is thus destabilised at moderate and 
low temperatures. Therefore, we need to be aware off and also report our subjective 
choices even for an automated preparation process. Enzyme-ligand formation is 
composed of two processes; desolvation of the ligand while binding and binding at the 
binding site. A designed model system not accounting for desolvation often prefers a 
ligand A over ligand B given that ligand A has a 9 kcal/mol desolvation barrier and a 
21 kcal/mol binding contribution, while ligand B with 3 kcal/mol desolvation barrier 
and 18 kcal/mol binding contribution. This is simply because the complex nature of a 
buffer makes it difficult to include. Enzymes might also have associations between 
water and the binding sites, which also need to be desolvated [467]. Ligands 
interacting with the active site zinc of metalloproteases needs to expel the recruited 
water molecule at a thermodynamic cost. This is also true for water associated with 






Fitting a ligand into the binding cavity of the receptor is referred to as docking [468]. 
Early day docking was limited to treating both the receptor and ligand as static 
structures. There are several approaches for performing docking, but it normally 
consists of two steps – finding the binding mode and scoring of these [353]. A small-
molecule has probably many binding modes inside the bigger enzyme, so normally 
the algorithm is also asked in this process to make a preliminary sorting. The 
algorithm finds the binding modes based on evaluation of physical and chemical 
complimentarily. There are of course many algorithms, which incorporates empirical- 
, force-field- or hybrid- notions on the system [469-475]. They also give different 
emphasis on contributions in the interface – physical or chemical complimentary. The 
algorithms are thus biased in their output dependent on their ability to- and how- they 
can interpret the input. The development of docking goes in many directions 
simultaneously, but two main branches seems to be working on improving 
calculations while the other explores ways of turning the static system into a more 
dynamic system. “induced fit” for instance tries to account for structural changes in 
the protein induced by the ligand thus creating a better fit and subsequently a different 
evaluation of the molecule [476, 477]. One of the ways to perform “induced fit” 
docking is to first do a preliminary docking and then investigate changes in that local 
environment that would improve the fit. If such a potential is found, the protein 
structure would be altered and the ligand would be re-oriented before the last scoring. 
With Figure 14, we can somewhat illustrate the problem that any algorithm encounter 
– what contributes to the binding? We see that the phenyl-group is physically very 
complimentary to the pocket. We also see that this pocket constitute different charges 
(illustrated with colours), and the ligand residues that are oppositely charged are 
placed next to them. Novel docking and scoring tools are continuously developed to 
improve “in silico” high throughput screening. An existing protein crystal with an 
identical or structurally similar inhibitor located at the binding-site can be used as a 
guide for the docking as well as for evaluating the ability to find correct poses [478]. 
Improvements in scoring can be done on training sets. Training sets are sets of 
compounds mixing a small set of active ligands with inactive decoy molecules. 








Figure 14: A small-molecular ligand docket inside one sub-pocket of Pseudolysin. The 
illustration is made within Maestro (Schrödinger).  
 
 
5.2.1 Docking with Glide 
Glide (grid-based ligand docking with energetics) is a docking program [426, 479]. In 
grid-based docking one defines a three dimensional space around the area one 
believes that the ligand will bind, and surface cavities on the receptor are identified. 
These potential binding sites are mapped for descriptors, such as hydrogen-bond 
donors and acceptors, metal ions and hydrophobic groups. Glide uses an empirical 
hierarchical-based approach for finding poses [426, 479]. Each ligand is dissected into 
a core region and rotamer groups (Figure 15). The core is what remains when each 
terminus of the ligand is severed at the “last” rotatable bond, while rotamer groups are 
attached to the core by rotatable bonds, but does not contain additional rotatable 
bonds. Carbon and nitrogen end groups terminated with hydrogen are not considered 
rotatable because their conformational variation is of little significance. Tautomeric 
states, ionic states and other descriptive properties are defined for each ligand before 





Figure 15: Core-region and rotamer-groups. The illustration shows a molecule where 
rotatable bonds (rotamers) are stripped, while cyclic-regions (cores) are shown in lines. The 
illustration shows 4 core-regions attached with 5 rotatable bonds. The illustration is made 
with ChemBioDraw Ultra version 12. 
 
During docking ligand conformations are evaluated and potentially eliminated as the 
pose search progresses and becomes computationally more demanding. Glide can 
incorporate so called constraints in one or several of the steps that will affect the 
outcome [426, 479]. A constraint is a ligand-receptor interaction (for instance a shared 
hydrogen-bond) or a ligand-feature (for instance a ligand core) that is specified by the 
user as essential or important before the evaluation of poses begins. Docked poses that 
fail to meet the requirements are rejected. Another final more elaborate scoring is 
performed on the top poses, and therefore the use of two different scoring functions in 














5.3 Free energy pertubation 
Perturbation theory is one of the oldest and most useful general techniques in applied 
mathematics [480]. Perturbation can mean to introduce several small changes in a 
physical system and thereby gradually altering it. The alchemic transformation is 
described by the numbers of intermediates generated and how these intermediates are 
different from each other. A term for the potential energy for the different 
conformations is created during the molecular dynamics (MD) simulation.  
 
16. UI = λ1UA + λ2UB 
 
Equations 16: UI is the potential energy of the intermediate and UA and UB are the two 
extremes, while λ1 and λ2 are ratio parameters. A coupling parameter λ can be the summation 
of the two (λ1 and λ2), which will add up to 1.  
 
The ensemble amount, which is the size of the collection of intermediates, is dictated 
by the rate at which λ1 and λ2 is changed. The changes between the intermediates can 
be made smaller (or “softer”) the larger the ensemble grows, which also would 
increase accuracy as sample size increases. The free energy can be calculated as a 
difference between two defined states (A and B) [481, 482].   
 
5.4 Linear interaction energy 
Linear interaction energy (LIE) - approach is a more recent method that can be used to 
find the free energy differences between ligand-enzyme complexes [482, 483]. The 
forces that contribute to ligand-binding are expressed as polar and non-polar 
contributions. Solvation free energies of non-polar molecules depend approximately 
on linear measures of physical characteristics, which enable an estimation of these 
forces by scaling of average Lennard Jones energies. Empirically fitted coefficients 
are found (α and β). An additional constant, γ, may be required to reproduce absolute 
binding free energies for instance if constant terms are affected by the protein 
environment, for instance hydrophobicity of the binding site. This coefficient will be 
specific for a given protein but conserved on any series of ligands studied on that 
protein. Molecular dynamics simulations are carried out on each ligand in two 
different surroundings (water or in a protein (with cofactors)-water solvent). The MD 
then enables us to find the convergent thermal averages of the molecules, which forms 
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the positional basis for finding interactive forces among atoms and ultimately leads to 
the calculation of ΔGbind. LIE spends more computational effort on physically relevant 
structures than on unphysical intermediates as with alchemical FEP [481]. LIE can be 
used to estimate free energy differences for compounds with bigger differences 
because of the emphasis of the solvent-solute interaction energies over the internal 
transformation process itself, while still deriving information from the force-field. It 
also seems robust for use with different force fields on the same ligands. Due to the 
fact that it is a recently developed method its validity has not yet been tested for a 
























Summary of manuscript 1  
 
Background and aim: 
PAC-1 has recently been shown to interact strongly with free zinc-ion, and has been a 
lead ligand scaffold for further drug testing by Hergenrother et al. Isatin,1,2,3 triazoles 
is a different inhibitor scaffold with many applications. Since MePs are depended on a 
catalytic zinc-ion, we set out to test the potency of these compounds towards several 
families belonging to the MA clan. Targeting these enzymes has either a direct 




Numerical values of inhibition (IC50 and KI) were found with a fluorescence-based 
FRET-assay. A single-cuvette flourecence-recorder was used with a recording time 
either of 1 minute or 10-15 minutes as specified in the manuscript. Two different 
substrates were used. Relevant enzyme-structures deposited in the Protein Database 
(PDB) were collected and the inhibitors were docked in the different enzymes using a 
Grid-based approach.   
 
Results and  Conclusion 
The ligands would inhibit the different targets within a low to high µM-range, and 
thus acted unselectively. Structural modification of the putative zinc-targeting group 
of PAC-1 reduced or deleted inhibitory strength. A more in depth examination of 
inhibition found that some of the compounds inhibited activated MMP-9 through a 
mixed inhibition mechanism, while had a competitive inhibition mechanism towards 
MT1-MMP. The reason for this is still unknown to us. We suggested a binding mode, 
based on docking, for all the compounds, and found that they could adopt several 
energetically similar poses in each active site. The inhibitors in low µM-range, 
interacted with the S1’-pocket of the MMPs. Structural changes on Isatin 1,2,3 







Summary of manuscript 2 
Background and aim: 
Therapeutic inhibition of several M4 enzymes in those diseases that they are involved 
is believed to be novel targets for future antibiotics. Targeting these enzymes has 
either a direct pharmaceutical application or a biotechnological one, as commented on 
in the thesis-introduction. Hydroxamates and retrohydroxamates are potent inhibitors 
of the MePs, expected to both target the catalytic zinc-ion and form favourable 
hydrogen-bond interactions inside the active sites. Due to their expected interactions 
with the catalytic-ion, several hydroxamate-derivatives were synthesised for 
evaluation as inhibitors of Thermolysin and Pseudolysin.    
 
Methods  
Numerical values of inhibition, IC50, were found with a fluorescence-based FRET-
assay. Measurements with either a single-cuvette flourecence-recorder or a plate 
reader were used with pre-incubation and recording time as specified in the 
manuscript. Two different substrates were used. The inhibitors were docked in the 
different enzymes using a Grid-based approach (Glide).  
.  
Results and  Conclusion 
Data analysis of IC50-values collected with the bradykinin-like substrate showed that 5 
out of 8 synthesised compounds displayed increased inhibition strength towards 
pseudolysin relative to thermolysin. Two compounds had the same value towards both 
enzymes, while two other had increased inhibition of thermolysin compared with 
pseudolysin. It was difficult to find a relative correlation between experimental results 
and modelling scoring, meaning docking scores or free energy calculations in LIE. 
The molecular modelling could be used to locate amino acids within 4 Å of individual 
compounds, and also explore important sub-site interactions. Strong interactions with 
amino acids in the S2’.pocket for ML25 and LM2 seems to be the main reason that 
they are quite strong pseudolysin inhibitors. Docking into Thermolysin, indicated the 







Summary of manuscript 3 
Background and aim: 
The enzymes in manuscript 2 were now attempted targeted with a different set of 
hydroxamates. These compounds now contain different backbone elements, compared 
among themselves and with those in manuscript 2, that are anticipated to interact with 
the substrate sub-pockets of Thermolysin and Pseudolysin.   
 
Methods  
The methods described in manuscript 2 were also used in manuscript 3. LIE 
calculations on MD simulations were performed.  
 
Results and  Conclusion 
Data analysis of IC50-values collected with the bradykinin-like substrate showed that 7 
out of 8 compounds displayed increased inhibition strength towards pseudolysin 
relative to thermolysin. One inhibited thermolysin better than pseudolysin. The 
strongest binders for both thermolysin and pseudolysin were SM10 and SM12, which 
both poses two ring systems.  The largest and most electron rich ring system occupy 
the S1 subpocket which is larger and more hydrophilic than the S2’ subpocket. The 



















There are several aspects of the work that could be debated in this section. However, 
this section will mostly be directed towards methods and data analysis. Exploration of 
these inhibitors as potential drugs towards MePs should be, in my opinion, left for the 
future. I hope that differences between “inhibitor” and “drug” were somewhat 
apparent to the reader in the introduction. “Scavenging inhibitors” is found here in the 
discussion more because it argues about the strategy of the work. The section could, 
but will not, investigate deeply into docking and LIE as methods despite the fact that 
this section is methods-oriented. I hope again that it was apparent to the reader that 
choices in parameters affect the outcome, and several methods and algorithms could 
be discussed potentially derailing the discussion with details.   
 
6. Scavenging inhibitors  
The word scavenging may refer to a search through refuse for salvageable material, 
and the work in the thesis may be seen as scavenging since all the inhibitors had other 
intended uses. That does not exclude that these uses can not co-exist and be utilised, 
but it affect the future of these inhibitors. In article 1, the target were originally pro-
caspase-3 [484], which is a pro-enzyme in the apoptotic signalling pathway. The first 
small molecule found to directly activate procaspase-3 was discovered in 2006, and 
was given the name PAC-1 (procaspase-3 activator-1) [484, 485]. Many compounds 
target early or intermediates in the signalling cascade, and therefore their effects 
might be absent in those cancers with deeper-downstream signalling errors. Most 
apoptotic signalling pathways affect the activation of procaspase-3 enabling active 
caspase-3 to hydrolyse many protein substrates. Thus, affecting the activation of 
procaspase-3 has potential in cancer intervention. The recent discovery of PAC-1, 
combined with the potency (relative to our findings) and also the fact that it targets a 
downstream target creating less side-effects, will contribute to the authors probably 
focusing on this biological target. The same can be seen from publications by our 
collaborators [486]. However, our future publication seems to be the first attempt to 
investigate inhibition properties of PAC-1, and derivatives, toward any metallo-
endopeptidase, so this might lead to more targets described for PAC-1 in the future. It 
will then be interesting to see if the new targets will be novel enough to spark an 
interest in synthesising PAC-1 derivatives for those new targets, and not just remain 
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off-target/side-effects parallel to the original use. The inhibitors used and described in 
manuscript 2 and 3 were given to us by two international collaborators [304, 487]. 
Selective targeting of MMP family members has been an aim for both these groups. 
However, they have also explored new targets for some inhibitors [487]. Our 
collaborators at the Pisa University have a broad competence in chemistry (synthesis 
and analysis), biological assays, and modelling, with several international 
collaborators. It might then be that they already have enough synthesis work planned 
for their original targets, and would be reluctant to perform synthesis only dedicated 
to our new targets. Then we are left with the scavenging role; only characterising their 
future designed MMPIs or TACE inhibitors, towards our targets (if they share their 
future endeavours with us). That does not mean that our findings with those inhibitors 
might not be interesting and lead to future publications. It just means that our 
modelling will be descriptive, and that potential prospective modelling predictions 
performed will not be followed up.  
 
7. Isolated Enzymes 
As stated in the introduction, our assays are dissected into; an enzyme component, a 
buffer environment and a way to detect and analyse strength and mechanism of the 
inhibitor. In article 1, several truncated recombinant Membrane-tethered enzymes, for 
instance MMP-14 and NEP-1, was used, and it is important to be aware of that these 
might act differently due to posttranslational modifications or the truncations made. 
MMP-9 and MMP-2 was activated by a proteolytic enzyme (MMP-9), trypsin, or an 
inter-autoactive process (MMP-2) (assuming that no trace contamination of other 
proteolytic enzymes is active in the bought sample). The activator can affect the 
binding and catalysis towards some substrates depending on cleavage site and what is 











Quenching refers to any process which decreases the fluorecence intensity of a given 
substance [488]. The FRET assay is a quenching mechanism since an energy donor is 
coupled to an acceptor. The donor reaches an excited state when light of absorbing 
energy is introduced, and this energy is transferred to the acceptor. The quenching is 
dependent on the donor – acceptor distance (r), falling off at a rate of 1/r6 and on the 
donor-acceptor spectral overlap and the relative orientation of the donor and acceptor 
transition dipole moments [488]. Enzyme cleavage between the donor and acceptor 
lowers the internal quenching, and light energy is now recorded by a detector. This is 
how we could connect enzyme activity to intensity of light production over time, 
while inhibition was inferred from the ability to lower light production by a supposed 
enzyme-interact. There are especially two causes, which we should be aware of, of 
quenching that might occur after the enzyme has cleaved the FRET substrate. The 
FRET-substrate might be at a concentration so that despite the enzyme-cleavage, 
intended to create distance between acceptor and donor, the donor will still have a 
non-covalently bonded nabouring acceptor “stealing” the light energy that should 
have been recorded by the detector. This is partly the reason why high substrate 
concentrations were avoided among other in finding some of the experimental kinetic 
values. Quenching could also be caused by the small molecular compounds tested as 
inhibitors (figure 16), especially aromatic ring structures at those light intensities in 
the experiments (300-400 nm). This quenching would be interpreted as part of the 
enzyme-inhibition, unless further investigated. However, quenching is most likely to 
occur with high concentration of the inhibitor [488]. Thus a poor inhibitor is more 
likely to be evaluated as a better inhibitor, but not a potential tight inhibitor since 
influence of quenching is, which was mistaken as true inhibition of the enzyme, lost at 




Figure 16: Quenching illustration.  The illustration shows an absorption peak (1) and the 
corresponding peak where a quenching molecule is added (2). The quenching molecule 
absorbs energy equivalent to the difference between peak 1 and peak 2.   
  
9. Inhibition: Data collection    
IC50-values were estimated based on plots of collected data on rates with or without 
different concentrations of inhibitor. The mode of operandum was different in 
manuscript 1 compared with manuscript 2 and 3. This because a single cuvette – 
recorder was used in manuscript 1. The single-cuvette-recorder is time-consuming 
since measurements are performed subsequently instead of in parallel. Analysis of the 
first measurement with an arbitrary inhibitor-concentration can also pinpoint other 
concentration to test. Thus it is possible to narrow the range of inhibitor-concentration 
to include the most vital parts of the activity curve (ranging from no-inhibition to 
more than 50 % inhibition). The plate reader (used in manuscript 2 and 3) analysis 
several samples, meaning inhibitor concentrations, simultaneously. In manuscript 2 
and 3 a wider range of inhibitor concentrations were tested, which often would range 








Figure 17: IC50-measurements. The illustration shows two graphs (Y-axis VI/V0 (rate with 
inhibitor versus rate void of inhibitor)) were the left has all the inhibitor concentration in one 
log (left), while the other (right) has inhibitor concentrations over a range of log-values. One 
log will then be a narrow inhibitor concentration-range, while a range of log-values includes a 
wider range of concentrations.  
 
10. Parameter assumptions in assay design  
The enzyme assays utilised in the work incorporates several parameters, constants in 
the experiments, and variables. In the phase were an assay protocol is established 
potential influences of the parameters should be tested. However, sometimes these 
tests are laboursome, and assumptions are made instead. The buffer composition is 
one of the factors that will influence assay results. In manuscript 1, HEPES was used 
instead of Tris-HCl because of the range of buffering capacity, we have utilised it 
before and also that it should contain less Zn2+ that might influence the inhibition 
capacity of our compounds. The inhibitors were all dissolved in 100 % DMSO. It 
might be that some (or all of the inhibitors) could be dissolved in a lower % of 
DMSO. This would in turn reduce the amount of DMSO present during data 
collection. An experiment to address DMSO effect on MMP-9 was performed, which 
found that DMSO reduces the enzyme activity (results not shown), potentially by 
denaturation or by interfering with optimal enzyme working conditions. It was also 
assumed that it would have a similar effect on MT1-MMP and the other enzymes. 
Therefore, DMSO was parameterised according to a dose that would allow us to 
replace it with larger concentrations of inhibitors during IC50-collection, but still 
retain a good measurable enzyme activity. DMSO was thus included at 5 % in all our 
experiments based on the initial testing on MMP-9. The alternative would be not to 
account for the added DMSO, but then it might have been that the inhibitors would 
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have been (wrongly) assumed to perform better simply because of activity reduction 
due to the addition of DMSO with the inhibitor. The addition of DMSO with the 
inhibitor is larger the more inhibitor is added to the solution. Small amounts of Brij35 
were added to the buffer because it has been shown to stabilise the gelatinases [489]. 
It was then included for all enzymes to make the buffer conditions as similar as 
possible. Brij35 may influence the catalytic activity and inhibition of proteinases 
[490]. Enzyme was added just before measuring, and therefore inhibitor and substrate 
competes immediately for enzyme-binding. The need to pre-incubate the inhibitors 
with enzyme without the presence of substrate, which is necessary for slow tight-
binding inhibitors, was again tested only with MMP-9 and assumed for the other 
enzymes (results not shown). It might be that a given inhibitor can act as a tight-
binding inhibitor on one enzyme and not require pre-incubation for inhibition of 
another one. It also might be that similar looking inhibitors act differently, again 
affecting the correctness of our assumptions. High amounts of CaCl2 were included 
while assaying, and we especially wanted to test if Ca2+ was similar enough to Zn2+ so 
that it would act as a competitive inhibitor-target for our inhibitors. Again MMP-9 
was used to test this. Due to how active MMP-9 had been purified, CaCl2 could be 
lowered to 333 µM in the assay. We established both a new Km-value and a new IC50-
value on PAC-1, and found no larger difference between the results with or without 
CaCl2 thus concluding that Ca2+ did not act as a competitive target for the inhibitor. 
Here an assumption is made that PAC-1 can represent all the inhibitors, which might 
be correct, partly correct (it might represent only the PAC-1 derivatives but not the 
Isatin 1,2,3 triazoles) or no inference should be made (PAC-1 only represents itself, 
having different qualities from all the other inhibitors). A second assumption is that 
MMP-9 is a good model for the other enzymes. This is probably less true since the 
different enzymes are found to respond to Ca2+ differently. However, CaCl2 was 









11. Kinetic Interpretations   
The paper is based on measured constants. Naturally it is important to evaluate the 
accuracy of the measurements and discuss the use of them throughout the article. The 
substrates were mostly chosen because of solubility and that we had worked with 
them in the laboratory before. Two different substrates had to be used simply because 
neither was suitable for use for all enzymes. Authors designing the synthethic 
bradykinin-substrate suggested that it was unsuitable for MMPs [374]. The Km-values 
for the enzymes toward their respective substrate was experimentally determined in 
duplicates (manuscript 1, table 1). Obtaining Km-values was important because the 
value provides an approximate quantitative measure of E-S complimentarily in 
binding, and is found from initial rates measurements over a range of [S]. In our 
experiments, we got a standard deviation of 30-40 %. It goes without saying that a 40 
% standard deviation points to low accuracy. The low accuracy of the Km will also 
have ripple effects on the determination of inhibition constants and the correlation 
between different types of constants. Table 2 presents the IC50-values determined 
under a discrete [S], and [S]/Km was attempted equal among some of the enzymes so 
to make the parameters similar between enzymes. A high standard deviation for Km 
translates into low accuracy also for [S]/Km. The Km-value is also implemented in the 
correlations between IC50-values and KI-values as illustrated also leading to lower 
accuracy in the inference on this correlation. Even though we might be able to 
measure our values accurately, there are potential experimental biases that we need to 
be aware off. The Km-value is found from initial rates measurements over a range of 
[S], and the choice and range of [S]s will create biases. Using [S] exclusively < Km or 
> Km will then result in accumulation of values on the two linear sections of the 
Michalis-Menten graph [491]. This will represent the phases where [S] is most 
limiting or non-limiting to the reaction respectively, and it will be difficult to infer the 
complete graph from either side. To avoid such biases a range going from (0.3 - 3) • 
km (or even better (0.1 – 10) • Km) is suggested including 6-7 individual 
measurements [491]. The individual measurements should be scattered evenly on the 







Figure 18: Kinetic interpretation of a MM plot. Plot 1 illustrates an experimental design with 
majority of points below putative Km, while plot 2 has majority of points higher than putative 
Km. As attempted explained in text and shown in illustration, these experimental designs will 
create uncertaintese in overall graph appearance and thus is unfit to find Km and Vmax. Plot 3 
has a good range in scatter of measurements, and it will be more likely to select one graph 
(line) instead of another (stripped line).     
 
We feared creating quenching at [S] > 10 µM, and did not include values of [S] over 
this threshold. A bias was thus created due to this for those enzymes with an expected 
Km-value above this threshold (for instance thermolysin, Pseudolysin and MMP-14, 
Table 1), where all the values are gathered < Km. NEP-1 and MMP-9 are less biased 
as it was possible to collect both above and below the expected Km-value. The high 
Km for MMP-14 creates a bias in the data set compared with that of MMP-9, which 
















12. Causality I 
There is a cause and effect relationship (also referred to as causality) between two 
events where one follows the first and is dependent on the occurrence of the first. In 
manuscript 1, we have studied causality in different ways. A putative effector/inhibitor 
was added to interfere with the natural process of an enzyme, and a good regression 
relationship was found between the addition of inhibitor and lowered enzyme activity. 
The IC50 is a value measuring the effect that one inhibitor has on a given system, in 
our case the FRET-based system. We would for instance expect to half the MMP-9 
activity with 46 µM PAC-1, final concentration under same experimental conditions, 
using the information collected in table 2. Expecting to find a physical interaction 
between enzyme and inhibitor, would allow the cause to either be that the inhibitor 
binds to one or both forms of the enzyme available ([E]free and [ES]).  
 
[I] + [E]free = [EI] (cause 1) → IC50 (effect)   
([I] + [E]free = [EI] (cause 1)) +  ([I] + [ES] = [ESI] (cause 2)) → IC50 (effect)   
 
Kinetic examination on a smaller inhibitor set allowed us to differentiate the two 
plausible cause explanations (Table 3) for those inhibitors. The physical interaction 
between enzyme and inhibitor was explored with theoretical calculations, docking. 
The interaction surface is found based on defined criteria’s optimising hydrophobic, 
hydrophilic, hydrogen-bonds and most often utilising surface cavities and prosthetic 
groups as potential mediators of interaction (we will not discuss the criteria’s). Cause 
1 is easier to explore for us because we have access to PDB-entries representing [E]free 
and we can compare our findings with literature - PAC-1 can be expected to target the 
zinc because it chelates free zinc and a binding mode is suggested. Cause 2 is very 
difficult to explore in any theoretical model, but especially docking because the 
protein is treated as very static. As explored in the introduction, these enzymes go 
through many dynamic movements to perform binding and catalysis of a substrate. 
There are also differences in movement dependent on the substrate, and we would not 
know how well the FRET-based system mimics a natural substrate. We would 
therefore not know what literature to compare to and incorporate in our model if we 
would be able to create a trustable model of [ES]. The interaction in ESI would also 
be difficult to trust because now we have no expected binding sites. However, key 
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amino acids in this new interaction site could be mutated in the enzyme and tested 
both in the FRET-based assay and the theoretical model. This requires a lot of extra 
work on something that might not be useful anyway. From a rational drug design 
perspective, we would like to dissect and isolate any key interacting sites and 
potentially modify and enhance them. The opposite is true for neutral or negative 
features that repel interaction. These compounds were expected to target the catalytic 
zinc, and therefore we would have that [E]free can be separated into catalytic zinc & 
overall topology. The enzymes that we have been working on have to “hidden” their 
active site differently from the exterior environment, so overall topology could mean 
global protein structures that determine accessibility to the active site, which 
potentially exclude a perfectly adapted inhibitor from entering into the active site in 
the first place. However, it seems that inhibitors gain entry into the active site inferred 
from the small differences in effect for a single inhibitor targeting enzymes with 
different active-site accessibility (Table 2). Thus, overall topology will be used to 
refer to structural features close to the zinc-ion (such as sub-pockets). The different 
scaffolds of the inhibitors allowed us to somewhat explore the individual 
contributions of these two enzyme features. Modification of the alcohol-group in 
PAC-1, which is suspected of zinc-interaction, led to decreased inhibition potency; 
replacement with a hydrogen-atom lead to no inhibition (PAC-1a) while other 
replacements (keeping the oxygen) decreased inhibition several folds. Comparing the 
inhibitors, we were allowed to conclude; 
 
1) Overall topology – interactions alone were not enough for inhibition (no 
inhibition with PAC-1a) 
2) Zinc-interaction (or groups suspected of zinc-interaction) was important for 
inhibition.  
 
Since the zinc-group alone (without the backbone) was not included in the study, 
further weighing of importance of the zinc-interaction could not be postulated. The 







o Is only the alcohol-group interacting with the catalytic zinc (monodentate-
binding)?  
o Is the alcohol group in combination other groups on the inhibitor (such as the 
ketone or electron-rich nitrogen or the aromatic side-chain) interacting with 
the catalytic zinc? 
o Can the receptor determine if both or one of them is used?  
 
The scaffold based on Isatin 1,2,3 triazole incorporated larger structural and chemical 
differences and the putative zinc-interaction group was different from PAC-1. As a 
group these inhibitors seemed to have a lower inhibition strength compared to PAC-1 
and PAC-1 analogues (except PAC-1a, 250D and 246C).  Docking revealed that 
scaffold differences altered the groups targeting the zinc-ion, and further sub-grouping 
of this scaffold was necessary. We found an interesting cause – effect relationship in 
ISD-1, TZ-5, TZ-8, were the longer P1’-chain (cause-factors) created a correlating 
effect.  A similar approach to causality was done in these papers as in paper 1, but the 
cause-analysis was somewhat different. The ZBG is the same for all the inhibitors, 
and it is viewed as a strong zinc-binding group. However, there are some 
contradictory results to be found in the literature as presented in the introduction. In 
manuscript 2 and 3, the near overlapping orientation of the ZBG-domain in the 
inhibitors allowed us to focus more on overall topology differences as a stronger 
contributor to inhibition strength than we could in manuscript 1. Moreover, a stronger 
computational examination was also performed accounting for both movement of the 
receptor as well as incorporation of water. The more reliable computations allowed us 
to further analyse contribution that causes the effects on individual receptor-inhibitor 
interactions.  









Future Perspectives  
We have in our manuscripts characterised sets of ligands, using a combination of 
experimental work and theoretical modelling. There are many possibilities left for us 
to continue with. We could continue a long time with the same inhibitors, trying to 
correlate new experiments with new modelling. The docking in manuscript 3 could 
for instance be followed up with MD simulations and LIE. In the laboratory, we could 
alter pH-conditions during measurements. The later would give us indications on how 
the equilibrium constants (KI and Km) are dependent on pH. We could also try to 
change ionic states of the ligands and active sites in our theoretical model accordingly. 
This might enable us to dissect and alter vital residues (either on the enzyme or on the 
ligand) in the enzyme-ligand interface. However, ligand binding is dependent on 
mutual interactions between ligand and enzyme, which are both affected by the pH. It 
would therefore be difficult to combine the correct protonic states in the modelling. 
The same is also valid for trying to construct a more accurate model of the E-S-I 
complex in manuscript 1.  We would rather like to move from describing these ligands 
into predicting new ligands to synthesis. Some of the tested compounds could serve as 
lead fragments for suggesting substituents and/or additions to the structures by the use 
of modelling, and then get the most interesting synthesised. For such a purpose, our 
present results are very helpful. . We have found structure-activity relationships, have 
a broad fundament for testing both selectivity and inhibition strength (both between 
families (inter) and inside families (intra)) and finally our results are that our 
inhibitors are weak inhibitors instead of strong inhibitors (suggesting possibilities for 
improvements). It is worth mentioning that co-crystals between inhibitors and 
enzymes could be sought. We have earlier made co-crystal between an inhibitor and 
thermolysin (PDB-entries: 2WIO, 2WHZ, unpublished paper [492]). We have in our 
modelling found differences in preferred binding mode between families so that a 
pose inside thermolysin might not represent that of a M10A enzyme. However, a co-
crystal with thermolysin might give information that can be applied on pseudolysin or 
other M4 members. The work was done in the tumour biology group, which works on 
cells and animals, and the inhibitors could be tested on different cell types. We would 
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